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Introduction: Efavirenz (EFV) is used in first-line antiretroviral (ARV) therapy of HIV-infected 
patients, and is principally metabolised by CYP1A2, CYP2A6, CYP2B6, CYP3A4/5 and the drug 
transporter ABCB1. Genetic variability in the above genes may contribute to differences in EFV 
plasma concentrations which affect the levels of viral suppression as well as development of side 
effects in patients. The aim of this project was to evaluate the effects of the different genetic 
polymorphisms on EFV plasma concentration levels in HIV/AIDS patients receiving first-line 
antiretroviral treatment (ART) containing EFV. 
Methods: Patients were recruited from Themba Lethu Clinic in Gauteng, South Africa. PCR/RFLP 
and SNaPshot were used to genotype for SNPs in CYP1A2, CYP2A6, CYP2B6, CYP3A4/5 and 
ABCB1 among 464 Bantu-speaking South Africans (301 HIV/AIDS patients and 163 controls). EFV 
drug plasma concentration levels were measured using LC-MS/MS. 
Results: We report baseline frequencies of the variant alleles of genetic polymorphisms in these 
genes in the Bantu-speaking South African population and their correlation, alone or in combination, 
with EFV plasma concentration. CYP2B6 516T, 785G and 983C alleles were associated with 
significantly high EFV plasma levels; while the CYP1A2 -163A allele showed a trend towards low 
EFV plasma levels in smokers. Combining CYP2B6 516T, 785G and 983C and CYP1A2 -163A 
alleles resulted in better prediction of EFV plasma levels. 
Conclusion: CYP1A2 and CYP2B6 are predictors of EFV plasma concentration in the Bantu-
speaking South African population, The CYP2B6 516T/T, 785G/G and 983C/C and CYP1A2 -
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Chapter 1: Introduction 
1.1. HIV/AIDS epidemiology 
The global burden of disease due to HIV-infection is extensive and over 33 million individuals 
[31.4-35.3 million] were living with HIV at the end of 2009. The HIV/AIDS prevalence in Africa 
varies substantially from as low as <1% in North Africa, to as high as 28% in Southern Africa 
(Figure 1.1). In Botswana and South Africa approximately 300 000 and 5.6 million individuals were 
HIV-infected at the end of 2009, respectively. AIDS-related deaths in 2009 were estimated at about 
6000 and 300 000 in Botswana and South Africa, respectively. In South African adults of 15 - 49 
years, the incidence of new HIV infections in 2009 was 1.49[1]. This evidently illustrates the need 
for effective management of HIV/AIDS in South Africa. 
 
 
















15 | P a g e  
 
Susceptibility to HIV-infection and progression into acquired immune deficiency syndrome (AIDS) 
is dependent on host genetic factors. The human leukocyte antigen (HLA) B*5701 class I allele is an 
example of a genetic factor that has been associated with slow progressing to HIV/AIDS in patients 
with stable CD-4 cell counts and HIV RNA levels < 50 copies/ml after two years of untreated 
infection[2]. With the high HIV prevalence in South Africa, it is priority to develop HIV/AIDS 
prevention programmes.   
1.2. Prevention of HIV/AIDS 
A number of HIV prevention interventions for the South African youth, including school and 
community-based programs (e.g. the Tshwane peer education and support programme) have a 
noteworthy impact on the improvement of HIV-related risk behaviours including condom use, HIV 
testing and alcohol use[3]. Large scale national AIDS awareness campaigns have been implemented, 
but the effect of these campaigns have not been systematically reviewed. 
Another approach to prevention of HIV/AIDS is the prevention of mother-to-child transmission 
(PMTCT). Guidelines proposed in 2010 include recommendations such as initiation of prophylaxis 
at 14 weeks of pregnancy for all HIV positive pregnant women[4]. However, besides the prevention 
of mother-to-child transmission, South Africa has an extensive antiretroviral therapy (ART) program 
involving more than a million HIV/AIDS patients[1]. 
1.2.1. Antiretroviral therapy (ART) 
Major progress in treatment of HIV/AIDS has been made since the discovery of the HI virus. 
Currently there are over 20 ARV drugs that function by targeting different steps in the HIV 
replication cycle. Table 1 lists all the ARV drugs that have been approved by the Food and Drug 
Administration (FDA) as of 31 July 2011. Approved ARV drugs are divided into six classes based 
on their mechanism of action[5]. Figure 1.2 is a diagrammatical presentation of the sites of action of 













16 | P a g e
Table 1: FDA approved ARV drugs (as of July 31, 2011). 
Class ARV Abbreviation Mechanism of action 
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Integrase inhibitors raltegravir RAL Inhibit HIV integrase 
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into the host genome. 
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Figure 1.2: Diagrammatical presentation of the sites of action of the various ARV classes 
(Adapted from Hazuda et al. [6]). 
 
As shown in Figure 1.2, fusion inhibitors prevent viral entry by binding to the viral envelope, while 
the integration of viral DNA into host DNA is avoided by integrase inhibitors. PIs bind to viral 
protease and prevent the cleavage of HIV proteins into mature viral particles[7, 8]. NNRTIs (e.g. 
EFV) function by binding non-competitively to HIV reverse transcriptase and lead to a change in its 
structure and function. The reverse transcriptase enzyme is then incapable of converting viral RNA 
into DNA preventing HIV viral replication[9].  
A combination of the drugs used in primary treatment is more effective in HIV/AIDS management 
and is commonly referred to as highly active antiretroviral therapy (HAART). HAART consists of 
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NRTIs with a NNRTI, one or two PIs, or a third NRTI depending on the ARV treatment 
recommendations of the country[11].  
1.2.2. ARV treatment recommendations 
The World Health Organisation (WHO) recommends ART initiation for all HIV/AIDS individuals 
with a CD-4 cell count < 350 cells/mm[3]. First-line therapy is recommended as a combination of a 
NNRTI and two NRTIs (e.g. lamivudine). Second-line ART consists of a ritonavir-boosted PI 
(atazanavir or lopinavir) and two NRTIs (zidovudine or tenofovir as used in first-line therapy)[12].  
In South Africa approximately 1.2 million people are currently undergoing ARV therapy at state 
hospitals[1]. All HIV/AIDS adults are started on a combination of 300 mg tenofovir (TDF), 150 mg 
lamivudine (3TC) or 200 mg emtricitabine (FTC) every 12 hours and 600 mg efavirenz (EFV) at 
night. Nevirapine (NVP) is used in cases where women cannot guarantee proper contraception or in 
cases of pregnancy during ARV therapy, because of the teratogenicity of EFV[13]. NVP is given in 
first-line treatment at a lead-in dose of 200 mg daily for two weeks followed by 200 mg every 12 
hours. The use of stavudine (d4T) is gradually being decreased due to its toxicity, thus it has been 
replaced by TDF, but is being continued in patients tolerating it. Patients presenting with renal 
disease are put on regimens containing AZT instead of TDF. In the South African setting, patients 
who do not respond to first-line treatment are switched to a combination of TDF, 3TC/FTC and 
LPV/r or AZT, 3TC and LPV/r, depending on the reason for treatment failure[14].  Although 
roughly 700 000 life years among adults have been gained due to ART between 1996 and 2009, 
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1.3. Complications of ARV treatment 
1.3.1. Treatment failure and viral resistance 
A considerable number of patients experience viral rebound and clinical progression to AIDS. 
Treatment failure, often defined as two consecutive viral load values of more than 5000 copies/ml, 
can be explained by the emergence of drug-resistant HIV and difficulties in maintaining long-term 
adherence to treatment[15]. Prolonged auto-induction of the enzymes involved in ARV metabolism 
can also lead to sub-therapeutic plasma concentration levels[16]. Repeated exposure to sub-
therapeutic ARV (e.g. EFV) drug plasma concentration levels can lead to the appearance of EFV-
resistant mutants in patients with low trough concentration levels. A single mutation (K103N) in the 
HIV reverse transcriptase gene has been reported to induce a high level of phenotypic resistance[17]. 
The combination of ARV drugs as well as concomitant treatment with other drugs can lead to 
significant drug-drug interactions. These interactions may also result in either sub-therapeutic or 
toxic drug concentration levels with a high risk for treatment failure or adverse drug reactions[9]. 
Treatment failure necessitates the change to different drug combinations or four drug regimens 
including both a NNRTI and a PI[11], which is expensive. Lifelong therapy is thus necessary to 
delay the development of drug-resistant viral strains, suppress HIV replication and reduce viral load 
by maintaining high drug levels in plasma and tissue[9]. Failure of ARV treatment to permanently 
eliminate HIV-infection after years of treatment and the development of ADRs are major 
limitations[8].  
1.3.2. Adverse drug reactions (ADRs) 
The most common reason for poor adherence is the development of ADRs after therapy 
initiation[18]. In the United States approximately 100 000 deaths per year are caused by ADRs[19]. 
Up to 40% of patients receiving EFV treatment experience central nervous system (CNS) adverse 
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severity and range from dizziness, insomnia, skin rash, bloating, nausea, diarrhoea and fatigue to 
hallucinations and dreams. However, the CNS adverse effects disappear in most of the HIV/AIDS 
patients and persist only in a proportion of individuals. EFV side effects occur more frequently and 
more severely in patients with high plasma concentrations of EFV. EFV plasma concentrations can 
thus be used to predict the efficacy of treatment and the occurrence of CNS ADRs[20, 21]. 
Discontinuation of EFV treatment occurs in approximately 4% of patients if adverse events are 
severe and persistent. The therapeutic range of EFV has been reported to be between 1 µg/ml and 4 
µg/ml and patients with sub-therapeutic plasma concentrations (below 1 µg/ml) have a higher risk of 
treatment failure and the development of drug resistance. An increased risk of CNS side effects 
resulted from plasma concentrations above 4 µg/ml[17]. Considerable inter-patient variability in 
response to EFV therapy has been observed, despite administration of the same EFV dosage. The 
inter-patient variability complicates the treatment of HIV/AIDS individuals notably. Other ARV 
drugs are associated with different ADRs but this project focussed on treatment with EFV. 
In the standard dose-response paradigm (excluding variability caused by non-adherence), 
pharmacokinetics (PK) describes the study of drug absorption, distribution, metabolism, elimination 
and toxicity (ADMET), while the relationship between drug plasma concentration and response to 
treatment is described by pharmacodynamics (PD). Inter-individual variability in drug and 
xenobiotic metabolism is extensive, resulting in ineffective drug treatment. ARV exposure in the 
human body is affected by the patient’s physiological parameters (e.g. age, body weight, gender, 
ethnicity, pregnancy and renal function), secondary diseases, drugs treating secondary diseases, diet 
and genetic polymorphisms in DMEs and transporters[22, 23]. Genetic variation accounts for a 
considerable amount of inter-individual variability and leads to impaired drug metabolism and 
transport (reviewed by Ingelman-sundberg [24]). For example, Autar et al. [25] reported on inter-
individual variability in drug plasma concentration for ritonavir boosted saquinavir in Thai and UK 
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As mentioned before, HAART, whose backbone is the concomitant administration of a combination 
of drugs, has the potential to result in adverse drug-drug interactions. These interactions can 
influence ADMET and complicate treatment[11, 27]. HIV/ AIDS patients are more prone to 
infection with Mycobacterium tuberculosis (TB) thus inevitably end up requiring treatment for both 
HIV/AIDS and TB. The co-administration of ART and anti-tubercular therapy is complicated by the 
resulting drug-drug interactions. The drugs used for TB treatment, rifampicin, pyrazinamide, 
isoniazid, and ethambutol, are substrates, inducers or inhibitors of enzymes involved in the 
metabolism of ART.  Rifampicin is an effective inducer of the CYP2B6 and CYP3A4/5 enzymes 
which are involved in the metabolism of both EFV and NVP[28, 29]. Rifampicin-based anti-
tubercular therapy has been reported to reduce EFV and NVP plasma concentrations by up to 
30%[30].   
1.4. Metabolism of ARVs 
ARVs from the different classes are metabolized by diverse enzymes in the small intestine and liver. 
Cytochrome P450 (CYP) enzymes are responsible for the bulk of all drug metabolism of clinically, 
physiologically, and toxicologically mportant compounds[31, 32]. Table 2 shows some of the 
compounds and drugs that are metabolized by enzymes that have been reported to play a role in the 
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Table 2: Examples of drugs that are metabolized by enzymes that participate in efavirenz 
metabolism (ARV drugs are highlighted). 




































































































RTV, a PIs that is often co-administered with IDV and SQV, is metabolised by CYP3A4/5[34, 35].  
Figure 1.3 shows the metabolic pathways of ritonavir. Ritonavir is principally metabolised through 
catalysis by CYP3A4/5, thus, RTV potently inhibits the CYP-mediated metabolism of other drugs 
that are also substrates of CYP3A4/5[35]. In addition, indinavir is also under the predominant 
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concentrations of other PIs (e.g. LPV/r) and ensures the achievement of therapeutic concentration 
levels[36]. 
Figure 1.3: RTV metabolism by CYP3A4/5 with the most dominant route of metabolism 
producing metabolite R3 (Adapted from Gangl et al. [37]). 
NVP is principally metabolized by CYP3A4/5 and other enzymes such as CYP2B6 have a minor
contribution. The four main metabolites of NVP: 2-, 3-, 8-, and 12-hydroxyNVP result from
metabolism mediated by CYP2B6, and CYP3A4/5 enzymes. Figure 1.4 shows the metabolic
pathway for NVP and the enzymes that are involved in the production of specific metabolites. Given
that the same enzymes involved in NVP metabolism are also involved in the metabolism of drugs 
used for TB treatment, there are vast implications of drug interactions[38]. Genetic polymorphisms 
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Figure 1.4: NVP metabolism by CYP2B6 and CYP3A4/5 (Adapted from Erickson et al. [40]; 
Cammett et al. [41]). 
EFV, which forms the major part of this study, goes through rapid absorption after oral 
administration and reaches maximum plasma concentrations in 3-6 hours. Therapeutic concentration 
levels are reached within a few days after treatment initiation. Steady-state EFV plasma 
concentrations is reached in 6-10 days after multiple dosing has been initiated in healthy 
individuals[42]. The prolonged half-life of EFV (approximately 40-55 hours after repeated dosing) 
allows for efficient repression of HIV replication and is good in treatment adherence[43, 44]. The 
narrow therapeutic range of EFV and correlation of high plasma concentration levels with severe 
CNS side effects are however a major problem in treatment of HIV/AIDS.   
Similar to NVP, EFV is principally metabolised by CYP2B6 to 8-hydroxy-EFV (8-OH-EFV), and to 
the minor metabolite 7-OH-EFV by CYP2A6, CYP2B6, CYP1A2, CYP3A5 and CYP3A4, in order 
of importance[43, 45]. EFV is also metabolised to the secondary metabolite N-glucuronide-EFV by 
UGT2B7[43, 45]. Figure 1.5 shows the EFV metabolic pathway. Due to the variation in the 
distribution in CYP2B6 genetic polymorphisms, Pfister et al. [46] showed a 30% higher hepatic 
clearance of EFV in Caucasians when compared to African Americans and Hispanics. In contrast 
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particularly, South African Bantu-speaking population is very limited. A PK study by Cohen et al. 
[47] in HIV/AIDS patients, investigated the effect of only one SNP CYP2B6 G516T and showed that 
this SNP is associated with high EFV concentrations and present in 32% Xhosa South Africans. This 
project therefore aims to investigate the combined effects of SNPs in the genes that have been 
associated with EFV metabolism. 
 
Figure 1.5: EFV metabolism by CYP2B6, with minor influence from CYP1A2, CYP2A6 and 
CYP3A4/5 (Adapted from di Iulio et al. [45]). 
However, it has been shown that not all patients experience the same effects to treatment and this is 
thought to be due to variability in the genes responsible for ARV metabolism and transport. A brief 
overview of each of the genes that forms part of this study will be given below. 
1.5. Variation in the enzymes associated with EFV ADMET 
CYP1A2 is one of the most abundant CYP enzymes expressed in the human liver, and contributes to 
about 13% of the total hepatic CYP content[48]. CYP1A2 metabolizes many drugs among them, 
phenytoin for treatment of epilepsy. CYP1A2 is not only responsible for the metabolism of EFV, but 
also endogenous compounds for example steroids as shown in Table 2. Smoking has been shown to 
induce CYP1A2 activity and alter drug response in treatment of Schizophrenia[49]. CYP1A2 is 
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CYP1A2 activity. Inter-individual variability in caffeine metabolism of as high as 60% has been 
reported previously[50-52]. Up to 70-fold variation in CYP1A2 activity and 15-fold variation in 
mRNA expression levels has also been observed among individuals[53, 54].  
The CYP1A2 enzyme is encoded by the CYP1A2 gene and located in a cluster with CYP1A1 and 
CYP1B1 on chromosome 15q24.1[55].  The CYP1A2 gene, which contains seven exons, is well-
conserved across humans and mice[56]. Polymorphisms in the CYP1A2 regulatory region have been 
reported (www.cypalleles.ki.se) of which the following polymorphisms have been documented in 
African populations: CYP1A2 C-163A, CYP1A2 T-739G and CYP1A2 C-729T[52, 57-60]. The 
CYP1A2 C-729T polymorphism is associated with decreased CYP1A2 expression, because of the 
elimination of an E-twenty six (Ets) nuclear factor binding site. The C-729T SNP has however only 
been observed at a frequency of about 3% in African populations together with the C-163A and T-
739G polymorphisms. The presence of the C-163A change in intron 1 has been largely associated 
with increased enzyme inducibility and activity[58, 61]. The C-163A SNP is the most widely studied 
CYP1A2 SNP and forms part of this investigation[58]. Several studies have described an influence of 
the C-163A polymorphism on response to antipsychotic drugs; with the -163A allele associated with 
lower drug concentrations and a higher risk of treatment failure and the -163C allele with higher 
drug concentrations and greater risk of ADRs[62]. There is nonetheless a need for studies with well-
defined phenotype groups of adequate sample size to determine the effect of genetic polymorphisms 
on enzyme activity and response to treatment. 
CYP2A6 enzyme is predominantly expressed in the liver and inter-individual variability of up to 
300-fold in activity has been reported by Xu et al. [63]. CYP2A6 is involved in the primary 
metabolism of nicotine, coumarin and also EFV (see Table 2)[64, 65]. Variability in CYP2A6 
activity has been reported to alter the risk of becoming nicotine dependent and the development of 
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with the CYP2A6 poor metabolizers being more frequent among Asians as compared to Caucasian 
individuals[67].  
The CYP2A6 gene, located on chromosome 19q13.2, is highly polymorphic with more than 30 
known alleles (www.cypalleles.ki.se). The polymorphisms are associated with abolished activity, 
reduced enzyme activity or increased gene expression and enzyme activity[67]. Among the 
polymorphisms identified, is a 58 bp gene conversion in the 3’UTR which is present at an allele 
frequency of about 30% in Caucasians, 40% in Asians, 55% in Canadian Native Americans and 10% 
in Africans[68]. The genetic polymorphism namely CYP2A6 G1093A was investigated in the present 
study and is located in a substrate recognition site in exon 7 of CYP2A6[64, 69]. The allele frequency 
for the G1093A polymorphism was below 10% in Caucasians and African Americans, with no 
information for the South African population[70, 71].  
CYP2B6 makes up 2%-10% of the hepatic CYP content and is expressed in the brain[17, 72-74]. 
CYP2B6 is responsible for the metabolism of approximately 4% of the FDA-approved drugs 
including EFV and NVP. Inducers of CYP2B6 expression include the TB drug rifampin, 
phenobarbital and phenytoin (see Table 2)[38, 43]. Inter-individual (20-250 folds) as well as ethnical 
variation in CYP2B6 expression has been reported by Code et al. [32]. Differential transcriptional 
regulation or genetic variation has been shown to result in altered enzyme functionality[75, 76].  
CYP2B6 (gDNA of 6968 bp) is located on chromosome 19q13.2, contains nine exons and encodes 
the CYP2B6 enzyme of 491 amino acids[77, 78]. CYP2B6 is highly polymorphic, with more than 70 
identified SNPs in intronic, exonic, and promoter regions[75, 76, 79]. Five mRNA splice variants 
have been identified for this gene and the most common splice variant (SV1) lacking exons 4 to 6, 
was linked to the G516T SNP in exon 4. The G516T SNP is responsible for aberrant splicing of pre-
mRNA by disruption of an exonic splice enhancer and leads to reduced functional mRNA and 
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A785G (K262R) SNP have been shown to exhibit 4-fold less protein expression in Caucasian 
individuals compared to individuals without these SNPs[18, 80]. The frequency of the CYP2B6
G516T SNP ranged from 14% in Koreans[81] to over 40% in Africans[79, 82] and 62% in Papua
New Guineans[83]. CYP2B6 SNPs show inter-ethnic variability and this may have serious
implications for treatment of HIV/AIDS taking into account that CYP2B6 principally metabolises
EFV and NVP. CYP2B6 516T and 983C variants diminish CYP2B6 enzyme activity resulting in 
lower EFV and NVP clearance (50-60%), increased steady-state plasma concentrations and a high 
frequency of CNS adverse effects[84-89]. The clinical relevance of CYP2B6 polymorphisms in EFV
metabolism has been studied to great extent in other populations but very little or no information is
available on South African patients. Even in situations where the polymorphisms have been studied,
very few have looked at the effects of combinations of SNPs on metabolism. Thus, this study
evaluated the role of the following SNPs: G516T, A136G, A785G, T983C and C1459T.
The human CYP3A subfamily encompasses CYP3A4, CYP3A5, CYP3A7 and CYP3A43.
CYP3A43 is believed to most likely not translate into active enzyme, while foetal hepatic CYP3A
activity is thought to be due to CYP3A7 and CYP3A5[90, 91]. CYP3A4 and CYP3A5 are both
expressed in the adult liver and intestine, while CYP3A5 is predominantly expressed in extra-hepatic
tissues. CYP3A4/5 account for approximately 30% of hepatic CYP expression and are responsible
for metabolism of a range of different xenobiotics including approximately 50% of currently
prescribed drugs as indicated in Table 2[31]. The substrate specificity of CYP3A4 and CYP3A5
overlap and include antiretroviral drugs such as ritonavir and saquinavir[35]. Knowledge of the
inducibility of the CYP3A4 enzyme is also important in combination therapy of HIV and TB, given
that the TB drug rifampicin is an effective inducer of CYP3A4[92]. Extensive variability in 
CYP3A4/5 protein expression was previously detected in the livers of Caucasian individuals, where
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nine times less expression[93]. In contrast, CYP3A5 is thought to be highly expressed in African and 
African-American individuals and this is of importance in the current study[94].  
The CYP3A gene family is located on chromosome 7, and CYP3A4 along with CYP3A5 was mapped 
to 7q22.1 by Inoue et al. [95] in 1992. CYP3A4 is about 27 kb in length and contains 13 exons, while 
CYP3A5 consists of nine exons and encodes a 502 amino acid protein[96, 97]. CYP3A expression is 
polymorphic with more than 40 allelic variants that have been identified in the CYP3A4/5 genes[97]. 
CYP3A4 A-392G polymorphism is located in the nifedipine-specific response element of the 
promoter region and in vitro expression analysis of this SNP produced conflicting results[98, 99]. 
The CYP3A4 -392G/G genotype has been associated with deterred enzyme activity and therefore a 
decrease in the rate of clearance of the anticonvulsant midazolam and immunosuppressant 
cyclosporine[100], while the same genotype was correlated to increased transcriptional activity[99]. 
Chu et al. [101] found that a small number of individuals with the -392G/G genotype had an elevated 
risk of developing endometrial cancer, but this study needs to be confirmed. The frequencies of the 
A-392G SNP ranged from being absent in Asians to 9% in Caucasians, 55% in African-Americans 
and 77% in Xhosa South Africans[102-104].  
Inter-ethnic variability in CYP3A5 expression is the reason for the absence of CYP3A5 in 70% of 
Caucasians and was linked to the CYP3A5 A6986G polymorphism. The 6986G allele results in 
alternative splicing of the transcripts and absence of CYP3A5 protein. The frequency of the 6986G 
allele were 95% in Caucasians, 73% in Chinese, 71% in Japanese, 70% in Koreans to 27% in 
African-Americans and 14% in Black Africans[97, 105]. CYP3A5 G14690A is a less common 
polymorphism that is present mainly in the African-American population. The 14690A allele causes 
a loss of protein activity by skipping exon 7 (alternative splicing) and leads to protein truncation[97]. 
Another polymorphism, the CYP3A5 27131-2insT leads to premature termination of the open reading 
frame by resulting in a shift in the reading frame. This polymorphism occurs at a frequency of 10% 
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polymorphisms of CYP3A5 have been studied in the South African population in the context of 
oesophageal cancer by Dandara et al. [105], but not with respect to HIV/AIDS therapy. The 
distribution of these polymorphisms in South Africa differed from that of other ethnic groups and 
individuals with abolished CYP3A5 enzyme activity had a reduced risk of developing oesophageal 
cancer[105]. A weak association between the CYP3A5 6986G/G genotype and increased risk of 
hepatotoxicity in patients receiving NVP treatment as well as higher EFV plasma concentration 
levels has been observed previously in other populations[84, 107]. Elucidation of the factors 
affecting an individual’s CYP3A4/5 enzyme activity could allow for individualized dose adjustments 
in therapies with drugs that are CYP3A4/5 substrates[106]. 
The P-glycoprotein (P-gp) encoded by ABCB1, is a 1280 amino acid protein expressed in the liver, 
adrenal gland, kidney, small and large intestines and brain. P-gp forms a dimer that results in a 
transmembrane pore on the epithelial cells lining the above mentioned tissue. This ATP-dependent 
efflux pump is responsible for the elimination of anticancer drugs, immunosuppressants, steroids, 
statins, calcium channel blockers, beta-blockers, antihistamines, anticonvulsants, antidepressants and 
the ARV drugs EFV, NFV and NVP (see Table 2)[108, 109]. P-gp transports substrates out of the 
blood brain barrier, excretes substrates into urine and limits absorption in the bowel. Expression and 
function of P-gp is influenced by environmental factors such as induction by other drugs. 
Interactions between compounds are substrate-specific, tissue-specific and concentration-
dependent[108].  
ABCB1 forms part of the ATP-binding cassette gene family (49 members) that encodes transporter 
(e.g. P-gp) and channel proteins. The ABCB1 gene is located close to ABCB4 on chromosome 
7q21.12, spans 209.6 kb and contains 29 exons[110]. The two exons closest to the ABCB1 promoter 
are untranslated and the mRNA is 4872 bp with the 5’UTR included[110, 111]. More than 1200 
SNPs have been identified in the ABCB1 gene, with about 20 synonymous and 40 non-synonymous 
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mRNA stability or splicing activity[112]. The three most common SNPs in the protein coding region 
are ABCB1 C1236T, T2677G/A and C3435T/A as shown on Figure 1.6. The C1236T polymorphism 
occurring in exon 13 does not result in any change in the amino acid sequence at residue 412. The 
frequency of the 1236T allele ranged from as low as 30% among Africans (this study) to 90% among 
Asians[112]. The T2677G/A SNP result in a change from serine to alanine or threonine at residue 
893. The C3435T/A SNP is one of three coding SNPs in ABCB1 and has been associated with 
reduced expression of P-gp in the intestines. The ABCB1 3435T allele does not result in any change 
in the amino acid sequence at residue 1145 in a cytoplasmic loop of P-gp[113]. Large inter-ethnic 
variability was observed for the C3435T/A polymorphism with the ABCB1 3435C allele present at a 
frequency of 83% in individuals from Ghana and Kenya[114].  
 
Figure 1.6: The position of common genetic polymorphisms in P-gp (encoded by the ABCB1 
gene) is shown with red “X” marks (Adapted from Kimchi-Sarfaty et al.[115]). 
The ABCB1 3435T variant has been linked to good immune recovery in HIV/AIDS individuals. The 
presence of the ABCB1 2677T and CYP2B6 516T variants has been strongly associated with 
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response[116-118]. Replication studies are thus necessary to understand the influence of ABCB1 
genetic variation on disease susceptibility, multi-drug resistance and drug-drug interactions[108]. 
However, not all the inter-individual variability in response to ARV treatment can be explained by 
genetic variation in the CYP and ABCB1 genes alone. The expression of these genes is controlled by 
nuclear receptors (NRs) for example the pregnane X receptor (PXR). Although they are not a major 
component of this project, nuclear receptors will be briefly reviewed in order to give a clear picture 
of the factors related to DME associated drug responses. 
1.6. Regulation of DMEs and drug transporters by nuclear receptors (NRs) 
Members of the nuclear receptor superfamily (NRs) are found in the cytoplasm and play a vital role 
in regulation of phase I and II DME expression[119]. These receptors are responsible for recognition 
of xenobiotics and then trigger their elimination through inducing DMEs and transporters. In their 
inactive form, NRs are bound to histone deacetylase complexes (HDACs). Upon ligand binding 
(xenobiotic or drug e.g. EFV) the HDACs are dissociated and the drug-NR complex is translocated 
into the nucleus. This complex then heterodimerises with retinoid X receptor (RXR) and binds to 
nuclear receptor response elements located in the promoter region of the genes responsible for drug 
metabolism. In addition to regulation by NRs, DMEs are also regulated by microRNA (miRNA). For 
example, CYP3A4, CYP2B6 and CYP2E1 have been shown to be regulated by microRNAs miR-
148a, miR-378 and miR-27a/b. Thus, any genetic variation at the level of the NRs and miRNA is 
bound to affect drug metabolism[120, 121]. It will be worthwhile to evaluate the effects of genetic 
variation at the level of miRNA and NRs in combination to that of DMEs on the response to 
commonly used therapy, in this case ART. Although the genetic variation in DMEs, NRs and 
miRNA is known for Caucasian and Asian populations, little (with respect to DMEs), almost nothing 
(with respect to NRs) and presently nothing (with respect to miRNAs) is known in African 
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1.7. Linguistic and genetic characterization of South African population
There are little genetic data on African populations with respect to pharmacogenetics. The few
studies that have been done have looked at single SNPs, thus failing to get the complete picture on
the functional effects of genetic variation in genes of pharmacogenetics relevance. This study makes
a valuable contribution by investigating the distribution of several polymorphic variants of
pharmacogenomics relevance, in the South African Bantu-speaking population. South Africa is made
up of four major population groups, Bantu-speaking Africans (80%), Mixed Ancestry (8%),
Caucasians (9%) and Asians, particularly Indians (2%) (www.statssa.gov.za). Data related to the
Mixed Ancestry, Caucasians and Asians can be inferred from previous studies that focussed largely
on Caucasians and Asians, but are not relevant to the Bantu-speaking South Africans. The Bantu-
speaking population group is hypothesized to have originated in West Africa between the present-
day Cameroon and Nigeria, near the Benue river, approximately 3000-5000 years ago (Figure 1.7). 
These populations are thought to have subsequently spread to east, west, central and southern Africa,
through one of the most studied human movements, the Bantu-migration[122]. 
In Africa, the Bantu languages are part of the Niger-Congo language family which together with
Nilo-Saharan, Afro-Asiatic and Khoisan, form the major language groups[123]. In South Africa, the
Xhosa, Southern Sotho, Zulu, Tsonga, Venda, Pedi and Tswana groups belong to what is loosely
referred to as the Southern branch of the Eastern Bantu languages. Although these groups originated
from a common ancestral population and were not isolated for long, their languages have diverged in
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Figure 1.7: Map of Africa showing the origin of the Bantu-speaking populations  and 
migration southward in different times and manners: first along the western coast and second 
along the eastern coast as shown in thick arrows (Adapted from Beleza et al.[125]). 
The genetic relatedness of the South African Bantu-speaking groups has been extensively 
characterised at the level of Y-chromosome DNA and mtDNA[126-128]. In general it has been 
observed that they share about 99% sequence similarity at the level of Y-chromosome DNA[124]. In 
addition, analysis at nine other STR autosomal DNA loci also revealed more than 99% 
similarity[124]. Besides genetic characterisation at the Y-chromosome and other loci, some work has 
also looked at mitochondrial DNA and the haplogroups frequently found in south-eastern Bantu-
speakers include L2a1b, L3e1 and L3e3[127].  
When genetic variation associated with response to treatment is taken into account, isolated and 
limited studies have documented the baseline frequencies of gene polymorphisms of 
pharmacogenomic importance in Bantu-speaking populations[129-135]. However, very little studies 
have been done using well characterized phenotypes to investigate the effects of such variation. This 
project therefore focuses on the aspect of pharmacogenetics of ARVs with an emphasis on the 
response to EFV treatment. 
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1.8. Aim and objectives 
The aim of the project was to investigate the role of genetic variation in CYP1A2, CYP2A6, CYP2B6, 
CYP3A4/5 and ABCB1 genes in response to treatment with EFV-based ART in a Bantu-speaking 
South African population. 
Objectives: 
 Baseline frequencies of previously characterized genetic polymorphisms in pharmacogenes 
were determined in a sample of healthy, Bantu-speaking South African individuals and the 
frequencies were compared to other populations. 
 The effect of identified genetic variations on the response to treatment with EFV-containing 
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Chapter 2: Materials and Methods 
2.1. Recruitment of research participants 
Four hundred and sixty-four (n=464) unrelated individuals from South Africa were recruited to 
participate in this study and informed consent was obtained from all subjects (Appendix A). These 
South African subjects were either healthy research participants (n=163) or HIV/AIDS patients 
(n=301). All subjects were black South African Bantu-speakers of different ethnic groups, including 
Zulu and Xhosa speakers. This study was approved by the University of Cape Town Health Sciences 
Faculty Research Ethics Committee, Cape Town, South Africa (REC REF: 103/2009) as well as by 
the University of Witwatersrand Human Research Ethics Committee, Gauteng, South Africa 
(M080124) as indicated in Appendix B. 
The healthy research participants were included as general population controls with no phenotypic 
data, and were not tested to determine HIV infection. The criteria for their inclusion were based on 
availability of adult Bantu-speakers from mainly Xhosa and Zulu groups, who did not present with 
disease. The HIV/AIDS patients were recruited prospectively from Themba Lethu clinic, Helen 
Joseph Hospital in Gauteng, South Africa and were on the following EFV-based regimens for at least 
six months; 3TC_TDF_EFV (n=25), AZT_3TC_EFV (n=62) and d4T_3TC_EFV (n=214). 
HIV/AIDS individuals were not newly diagnosed and included in the study based on the availability 
of the following information from a questionnaire: age, gender, ethnicity, and disease stage, body 
mass index (BMI) at baseline, level of education, employment, smoking and alcohol use. The CD-4 
cell count, viral load, haemoglobin levels, aspartate transaminase (AST) and alanine transaminase 
(ALT) levels were available from the clinic patient records. The CD-4 cell count and viral load was 
available at baseline as well as six months after treatment initiation. Detailed recordings on the ART 
regimens (start and end date), change in regimens as well as treatment adherence and the use of other 
concomitant medication were also provided. Only patients who were on treatment for at least six 
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2.2.  Sample collection  
2.2.1. EFV plasma sample preparation 
A 5 ml whole blood sample (in EDTA-containing Vacutainer tube) was collected from each patient 
between 14 and 18 hours post EFV dose. Plasma was obtained from the blood samples by 
centrifugation at 700 x g for 5mins, and stored immediately at -80⁰C until pharmacological analysis.  
EFV plasma concentrations were determined by liquid chromatography (LC) and triple-quadrupole
tandem mass spectrometry (MS/MS) (API 4000 triple quadrupole MS/MS Applied Biosystems, 
South Africa) using a modification of the method by Chi et al. [136], in the Division of Clinical
Pharmacology, University of Cape Town. LC-MS/MS is a technique used to separate compounds
based on their physical properties such as hydrophobicity, and their mass. LC-MS/MS allows for the
detection and concentration measurement of a compound (e.g. EFV and EFV metabolites) within a
complex mixture.
An aliquot of 500 μl of precipitation reagent (80% methanol: 20% 0.2M ZnSO4 v/v) (methanol from
Merck KGaA, Darmstadt, Germany; ZnSO4 from Sigma Chemical Co.) with reserpine (Sigma 
Chemical Co.) at 0.4 μg/ml as internal standard was added to a 50 μl aliquot of the plasma sample
and mixed at high speed for 15s. The suspension was then sonicated for 10mins and centrifuged at
4000 x g for 10mins to precipitate and remove the proteins. The extracts were transferred to vial
inserts and placed in the autosampler tray for injection onto LC/MS/MS column (Phenomenex 
Gemini C18, 50× 2.00 mm, with 5 micron particle size packing).
2.2.2. EFV plasma concentration assay by LC/MS/MS 
Mobile phase A was 10% methanol and mobile phase B was 90% methanol: 10% 10mM of 
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0.20mins, switched to 100% phase B for 0.21mins, held at 100% phase B for 2.79mins. Then 
returned to 100% phase A for 0.10mins and held for a further 3.90mins prior to the injection of 
another sample. The total run time for each sample was 7.00mins. The flow rate of mobile phase was 
kept constant at 500 μl/min. The volume of injection was 5 μl. 
The plasma calibration curves of EFV (Merck Research Laboratories, Rahway N.J., USA) were 
linear over the range of 0.20-20.00 mg/l. Plasma calibration curves were prepared by spiking EFV in 
drug-free plasma at each calibration concentration. Three quality controls were prepared in the same 
manner (0.3 mg/l, 4 mg/l and 11 mg/l) for EFV. The lower limit of quantification (LLOQ) for EFV 
was 0.10 mg/l. A sample with plasma concentrations below the LLOQ was treated as 40% of LLOQ 
concentration in the data analysis. Samples with plasma concentrations higher than the upper limits 
of quantification were diluted with drug-free plasma and re-analysed. 
Accuracy of the EFV plasma concentration assay was above 90%. The intra-day and inter-day 
precisions ranged from 1.34% to 9.61% and from 2.23% to 7.04%, respectively (Appendix C). 
2.2.3. DNA isolation and integrity check 
DNA was isolated from the healthy participants in the Division of Human Genetics, University of 
Cape Town. DNA isolation from the 5 ml whole blood was completed according to the method 
adapted from Gustafson et al. [137]. The salting-out method involves lymphoblast cell lyses using 
Sucrose Triton-X (Sigma-Aldrich, St Louis, MO, USA) and T20E5 (Sigma-Aldrich, St Louis, MO, 
USA and Promega Corporation, Madison, WI, USA) lysis buffers, the use of high salt concentrations 
for the removal of proteins, followed by ethanol precipitation of the DNA (Merck, Darmstadt, 
Germany). DNA samples were stored at 4⁰C during genetic analysis. 
Buffy coat and plasma samples were obtained from the whole blood sample collected from each 
HIV/AIDS patient, by centrifugation at 4 000 x g for 10mins. 400 µl plasma and 200 µl buffy coat 
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and GENelute (Sigma-Aldrich, St Louis, MO, USA) extraction methods, respectively. DNA was 
bound to a silica membrane (as a result of the lower pH) within the spin column and contaminants 
were removed by washing of the spin column. DNA was then eluted from the silica membrane using 
elution buffer. The QIAmp spin protocol for 0.3 – 1 ml whole blood was used with the following 
deviations; centrifugation steps were performed at 2000 x g and extended to double the time 
described in the protocol (in order to efficiently remove impurities), DNA elution with 150 µl elution 
buffer was extended to overnight and repeated to yield maximum DNA concentrations. The 
GENelute spin protocol (using up to 0.2 ml whole blood) was adapted by repeating the DNA elution 
step twice overnight, using 200 µl elution solution. The integrity of the DNA samples was checked 
after extraction, using a UV-spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA) as 
well as agarose gel electrophoresis (Appendix D). 
2.3. Gene annotation and primer design 
DNA sequences were attained from the ENSEMBL website (URL: http://www.ENSEMBL.org) and 
the NCBI Gene website (URL: http:// ncbi.nih.gov). These DNA sequences were annotated using the 
program Perl version five, created by Dr. Rebello (Division of Human Genetics, UCT, Personal 
communication) to show the gene structure and previously identified genetic variation.  
The following free web-based programs were used to determine the specificity of the primers to the 
human genome (including the region of interest), to calculate product length, the melting 
temperature, and the GC-content of the designed primers; NCBI Primer-BLAST[138] which can be 
found at the following URL: http://www.ncbi.nlm.nih.gov/tools/primer-blast/, Primer 3 version 2004 
which was developed by Rosen and Skaletsky [139] in 2000 (URL: http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi) and the IDT Oligo Analyzer from Integrated DNA Technologies 
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length and had a 50%-60% GC-content. Primer pairs had a difference in melting temperature of less 
than 5°C and were ordered from Integrated DNA Technologies. 
2.4. Genotyping of genetic polymorphisms 
The genetic variants investigated in this study as well as the genotyping method used is indicated in 
Table 3 below. The number of individuals with genotypic data available was also reported. The allele 
frequencies of the healthy volunteers where compared to allele frequencies previously reported for 
the Yoruba, African-American and Caucasian populations (National Centre for Biotechnology 
Information (NCBI) dbSNP database (http://www.ncbi.nlm.nih.gov/) and frequencies for Xhosa, 
Luhya and Maasai individuals were obtained from Ikediobi et al. [104].  
Table 3: List of genes and SNPs genotyped in this study.
Gene ENSEMBL 
Accession 




rs762551 -163C>A C A 242 PCR/RFLP 
CYP2A6 ENSG0000025
5974 
rs28399454 1093G>A G A 458 PCR/RFLP 
CYP2B6 ENSG0000019
7408 
rs35303484 136A>G A G 460 SNaPshot 
CYP2B6 rs3745274 516G>T G T 460 PCR/RFLP 
CYP2B6 rs2279343 785A>G A G 458 PCR/RFLP 
CYP2B6 rs28399499 983T>C T C 451 SNaPshot 
CYP2B6 rs3211371 1459C>T C T 461 PCR/RFLP 
CYP3A4 ENSG0000016
0868 
rs2740574 -392A>G G A 187 PCR/RFLP 
CYP3A5 ENSG0000010
6258 
rs55817950 3699C>T C T 460 SNaPshot 
CYP3A5 rs776746 6986A>G G A 455 PCR/RFLP 
CYP3A5 rs10264272 14690G>A G A 457 PCR/RFLP 
CYP3A5 rs41303343 27131-2insT - T 460 PCR/RFLP 
CYP3A5 rs28383479 19386G>A G A 460 SNaPshot 
CYP3A5 rs15524 31611C>T C T 457 SNaPshot 
ABCB1 ENSG0000008
5563 
rs9282564 61A>G A G 460 SNaPshot 
ABCB1 rs1128503 1236C>T T C 460 SNaPshot 
ABCB1 rs1045642 3435C>T/A T G/A 460 SNaPshot 
ABCB1 rs2032582 2677T>G/A T G/A 456 SNaPshot 
ABCB1 rs3842 4036A>G A G 460 SNaPshot 
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2.4.1. Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) 
genotyping 
Genetic polymorphisms of pharmacogenetics relevance in CYP1A2 (C-163A), CYP2A6 (G1093A), 
CYP2B6 (G516T, A785G and C1459T), CYP3A4 (A-392G) and CYP3A5 (A6986G, G14690A and 
27131-2insT) were genotyped using PCR-RFLP (see Table 4) according to the methods of Pavanello 
et al. [140], Fukami et al. [141], Lang et al. [75], van Schaik et al. [142] and van Schaik et al. [93], 
respectively. 
The primer annealing temperature (Ta) was estimated from the melting temperature (Tm) of a primer 
set, as Ta (°C) = Tm – 5⁰C. The Tm was calculated based on the nucleotide composition of the primer 
sequence, using the formula: Tm (°C) = 2(G+C) + (A+T). A temperature gradient PCR was used to 
establish the optimal Ta for each primer set (Table 4). PCR amplification was performed using the 
“MyCycler
TM 
Thermal Cycler” from Bio-Rad (Bio-Rad Laboratiories, Hercules, CA, USA). PCR 
cycling conditions was set up at 94⁰C for 3mins, and then repeated 40 cycles with 94⁰C for 30s, the 
optimal Ta for each primer set (Table 4) for 30s and 72⁰C for the specific extension time (Table 4), 
followed by 72⁰C for 10mins. 
The PCR reaction contained the following reagents at final concentrations: 50-100 ng DNA, 1X 
GoTaq poly flexi reaction buffer (Promega Corporation, Madison, WI, USA), 0.4 mM of each 
dNTPs (Bioline, London, UK), 1.5 mM MgCl2 for all SNPs except CYP1A2 C-163A which required 
1.25 mM (Promega Corporation, Madison, WI, USA), 0.4 µM of each forward and reverse primer 
specific to the genetic variation (Integrated DNA Technologies, Inc., Coralville, IA, USA), 0.1 µl 
GoTaq flexi DNA polymerase (Promega Corporation, Madison, WI, USA) and the volume was 
made up to a total of 25 µl using sterile distilled water (sdH2O). The presence of the expected PCR 
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using EtBr staining (Sigma-Aldrich, St Louis, MO, USA). Tables 4 and 5 show the PCR conditions 
and either the RFLP or SNaPshot conditions that were used in the genotyping of the 19 SNPs. 
In the case of RFLP, PCR amplification was followed by digestion of each specific PCR product 
using the appropriate restriction endonucleases as specified in Table 4. The digestion reaction 
contained the following reagents: 10 µl of PCR product, 1X specific restriction buffer (Fermentas 
Life Sciences, Burlington, Canada), 3 U restriction enzyme (Fermentas Life Sciences, Burlington, 
Canada), and made up to a total volume of 30 µl with sdH2O. The digestion reaction was incubated 
for at least two hours at the temperature mentioned in Table 4. Digestion products were separated on 
a 2.5% or 4.5% (w/v) agarose gel at 160 V for 45mins and visualised using EtBr staining. 4.5% 
(w/v) agarose gels were prepared for the separation of small DNA fragments, using NuSieve®3:1 
and SeaKem agarose (Roche, Mannheim, Germany) in a 2:1 ratio. The restriction patterns (Table 4) 
indicating the presence or absence of the genetic variation and were used to determine the genotype 
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Table 4: Parameters and conditions used in the PCR-RFLP genotyping protocols (All PCR 
reactions required 1.5 mM MgCl2 except the CYP1A2 C-163A which required 1.25 mM). 
SNP Primer sequence  (5’-3’) Ta, ext  PCR 
product  









































































































* Mismatches with the CYP3A4 and CYP3A5 reference sequences are underlined. References; 1= Pavanello et 
al. [140], 2= Fukami et al. [141], 3= Lang et al. [75], 4= van Schaik et al. [142], 5= van Schaik et al. [93]. 
 
2.4.2. SNaPshot genotyping 
The ABI prism SNaPshot multiplex method was used to genotype two polymorphisms in CYP2B6 
(A136G and T983C), three polymorphisms in CYP3A5 (C3699T, G19386A and C31611T) and five 
polymorphisms in ABCB1 (A61G, C1236T, C3435T/A, T2677G/A and A4036G). The SNaPshot 
method follows PCR amplification of the DNA sequence region of interest, and involves the 
annealing of an internal SNaPshot primer directly adjacent to the genetic polymorphism. Single base 
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incorporated, resulting in sequence termination. The ddNTPs are labelled as follows: ddATP – dR6G 
(green), ddCTP – dTAMRA
TM
 (black), ddGTP – dR110 (blue) and ddTTP – dROX
TM
 (red). The 
SNaPshot
TM
 multiplex kit allows for the genotyping of up to ten genetic polymorphisms 




 was used as size-standard and the ABI 
3130xl Genetic Analyzer (Applied Biosystems, Carlsbad, CA, USA) was used for genetic analysis. 
PCR amplification of the DNA regions surrounding the genetic polymorphisms was performed in 
combination as shown in Table 5. The “MyCycler
TM 
Thermal Cycler” from Bio-Rad (Bio-Rad 
Laboratiories, Hercules, CA, USA) was used with the PCR cycling programme as 94°C for 3mins, 
and then repeated 40 cycles at 94°C for 30s, the optimal Ta for each primer set (Table 5) for 30s and 
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Table 5: PCR and SNaPshot amplification conditions for 10 SNPs (all required 1.5 mM MgCl2 
except CYP2B6 T983C which required 2.5 mM). 









































































SNaPshot primer: ACTCGTCCTGGTAGATCTTGAAGGG 
54⁰C, 
40s 

























SNaPshot primer: CTCCTTTGCTGCCCTCAC 
51⁰C, 
50s 
149 A 5. 
References; 1= Lang et al. [75], 2= Lee et al. [143], 3= Liou et al. [144], 4= Rhodes et al. [145] and 5= 
designed. 
5 µl of each PCR product was pooled and 10 µl of the combined PCR products were used during the 
first shrimp alkaline phosphatase (SAP) and ExoI clean-up. The SAP and ExoI reaction contained: 
1.5 U SAP (Fermentas Life Sciences, Burlington, Canada), 2 U ExoI (Fermentas Life Sciences, 
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(sdH2O). The SAP and ExoI reaction was incubated at 37⁰C for 1 hour and the enzymes were 
inactivated at 75⁰C for 15mins. 
SNaPshot single base extension of the genetic polymorphisms was performed in combinations; A, B 
and C (as shown in Table 5). The “GeneAmp
®
 PCR System 9700 version 3.08” (Applied 
Biosystems, Carlsbad, CA, USA) was used with the SNaPshot cycling programme as 96°C for 10s, 
and then repeated for 25 cycles at 50°C for 5s and 60°C for 30s. 
The SNaPshot reaction contained the following reagents at final concentrations: 5 µl, 5 µl and 1 µl
PCR product from each sample for combinations A, B and C, respectively. 1 µl SNaPshot multiplex
ready reaction mix, pooled internal SNaPshot primers were designed and is shown in Table 5
(Integrated DNA Technologies, Inc., Coralville, IA, USA) and the volume was made up to a total of
10 µl using sterile distilled water (sdH2O). The second shrimp alkaline phosphatase (SAP) clean-up 
was performed by adding 1 U SAP (Fermentas Life Sciences, Burlington, Canada) to the total
SNaPshot reaction volume of 10 µl. The SNaPshot reaction was incubated at 37⁰C for 1 hour, the
enzyme was inactivated at 75⁰C for 15mins, the SNaPshot products denatured at 94⁰C for 5mins and
placed on ice until capillary electrophoresis. 




(Applied Biosystems, Carlsbad, CA, USA) and 4
µl HiDi formamide was added to 5.75 µl SNaPshot product and capillary electrophoresis was
performed using a ABI 3130xl Genetic Analyzer (Applied Biosystems, Carlsbad, CA, USA).
SNaPshot results were analysed on the GeneMapper © Software version 4.1 (Applied Biosystems,
Carlsbad, CA, USA).
2.4.3. Cycle sequencing 
Direct cycle sequencing was used to identify novel genetic polymorphisms in CYP2B6, CYP3A5 and 
ABCB1, as well as confirm the genotyping results from three individuals of each genotype per SNP. 
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terminator mix and sequencing buffer, was used. The terminator mix contained the ddNTPs, as well 
as the thermo-stable DNA polymerase. The sequencing reaction (20 µl) included 2 µl PCR product, 
0.5 X terminator mix, 10 pM of primer and 1 X sequencing buffer. Sequencing reactions were made 
up to 20 µl with sdH2O. The cycling conditions of the sequencing reaction used an initial 
denaturation step at 98°C for 5mins, 30 cycles consisting of a denaturation step at 96°C for 10s, an 
annealing step at 50°C for 15s and an extension step at 60°C for 4mins. 
Clean-up of the cycle sequencing reaction was required to remove unincorporated ddNTPs and 
excess primer, also to precipitate the sequencing product. This involved the addition of 44 µl 
absolute ethanol and 2 µl 5 M sodium oxaloacetate (pH 4.5) to each reaction, followed by storage at 
-20°C for a minimum of two hours. After storage at -20°C, the supernatant was removed by 
centrifugation at 10 000 RPM for 5mins. 40 µl 70% (v/v) ethanol was added, to remove the absolute 
ethanol and samples were centrifuged at 10 000 RPM for another 5mins. The supernatant was 
discarded and the samples were left to air-dry for at least 30mins. Sequencing samples were 
resuspended in 10 µl sdH2O and analysed on an ABI 3130xl Genetic Analyzer (Applied Biosystems, 
Carlsbad, CA, USA). 
Sequencing analysis was performed using Bioedit Sequence Alignment Editor version 7.0.0 (Tom 
Hall, Isis Pharmaceuticals, Inc.) and all sequences were aligned to the reference gene DNA 
sequences database using the ClustalW multiple alignment accessory application. 
2.5. Statistical analysis 
 
Statistical analysis was performed using Microsoft Excel 2010 (Microsoft Corporation, Redmond, 
WA, USA) to calculate Hardy-Weinberg Equilibrium (HWE), while GraphPad Prism version 5 
(GraphPad Software, Inc, La Jolla, CA, USA) and Statistica version 10 (StatSoft Ltd, Atterbury, UK) 
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performed using SHEsis. SHEsis infers haplotypes using a PL-CSEM (Partition-Ligation 
Combination-Subdivision Expectation Maximization) algorithm based on the standard Expectation 
Maximization (EM) algorithm but with the improvement of estimating haplotypes from a large 
number of individuals and multi-allelic loci. In the first step some alleles are combined randomly to 
construct an optimum set of candidate haplotypes with frequencies greater than a threshold value 
(using the EM algorithm). In the subdivision step the alleles are subdivided in two to form the set of 
candidate haplotypes for the next EM step [146, 147]. A p-value <0.05 was considered statistically 
significant and a p-value <0.1 was considered a trend. 
2.5.1. Sample size calculation 





. Z is defined as the value for 95% confidence, d is a α-value = 0.05, while p 
and q are the frequency of the variant allele and 1-p, respectively. A Z-value of 1.96 and allele 











N = 138 samples 
2.5.2. Genotype-Phenotype analysis 
Drug plasma concentration levels from time-point A and time-point B were noted for each sample 
and the change in EFV concentration levels were also calculated. The distribution of mean drug 
plasma concentrations was established and normality of the data were tested using the Shapiro-Wilk 
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The effect of patient demographic and clinical parameters on average EFV plasma concentration was 
assessed by Mann–Whitney rank sum test and Chi
2
-analysis (for gender, alcohol consumption, 
tobacco smoking, opportunistic infection and change in drug regimen) or by Spearman correlation 
and Kruskal-Wallis one-way analysis (for age, BMI, CD-4 cell count, viral load, haemoglobin levels, 
AST levels and ALT levels). 
The effect of genetic polymorphisms in CYP1A2, CYP2A6, CYP2B6, CYP3A4/5 and ABCB1 on 
average drug plasma concentration, CD-4 cell count, viral load and opportunistic infection was
measured by Kruskal-Wallis one-way analysis or by Mann-Whitney rank sum test. The combined
effect of genetic polymorphisms was performed using Kruskal-Wallis one-way analysis and
followed by Dunn’s post test for multiple comparisons. Chi
2
-analysis was carried out to investigate













50 | P a g e
Chapter 3: Results 
3.1. Study subjects and demographic characteristics 
The study cohort (n=464) consisted of 163 healthy research participants and 301 HIV/AIDS patients.
The clinical and demographic characteristics of the study participants are presented in Table 6.
About 67% of the healthy participants were females; less than 20% of all the healthy participants
smoked tobacco and about 40% consumed alcohol. The average age (±SD) of the study participants
were approximately 38 (±12.28) years. 
Efavirenz plasma concentration levels were available for 156 of the 301 patients and information
regarding disease stage was available for 286 of the patients. The current study is ongoing and
information on disease stage is available from hospital records and therefore updated regularly and
also available for all the patients and not only the patients with EFV plasma concentrations. Disease
stage 1 is defined by the World Health Organization as asymptomatic HIV-infection with persistent
generalized lymphadenopathy, while disease stage 2 is defined by unexplained moderate weight loss,
recurrent upper respiratory tract infection and infection with Herpes zoster or Angular cheilitis.
Disease stage 3 is defined by unexplained severe weight loss and disease stage 4 is termed HIV
wasting syndrome. Most (63%) of the HIV/AIDS patients were classified as disease stage 1. The
average (range) EFV plasma concentration was 4.64 (0.6 – 22) µg/ml, while the average (range) for
time-points A and B were 4.78 (0.2 – 34) µg/ml and 4.61 (0.2 – 31.8) µg/ml, respectively.
HIV/AIDS patients had an average BMI of 23.23 at baseline. The average CD-4 cell count and viral
load of patients initiating ARV treatment was 136.09 (±113.24) cells/µl and 26917.71 (±27133.50)
copies/ml, respectively. After 6 months of first-line ARV treatment, the average CD-4 cell count
almost doubled, while the average viral load was about 18-times less than at baseline. 21% (n=54) of
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IU/l and 20% (n=50) with ALT levels above 40 IU/l. Non-ARV medication co-administrated with 
EFV included mainly bactrim, vitamin B and rifampicin and 42% of HIV/AIDS patients had 
opportunistic infections. Four patients reported to have missed a day of treatment.  
Table 6: Demographic characteristics of the healthy research participants and HIV/AIDS 
 Healthy research participants 
(n=163) 
HIV/AIDS patients (n=301) 
Ethnicity Bantu-speaking Bantu-speaking 






8        (15.4%) 
22      (42.3%) 
8        (15.4%) 
20            (6.9%) 
28            (9.7%) 
11            (3.8%) 
Mean age (years) 35.77 (±13.96) 41.29       (±9.3) 
Mean BMI (kg/m
2
) N/A 23.23       (±4.74) 
Average viral load at baseline 
(copies/ml) 
N/A 26917.71 (±27133.50) 
Average CD4 count at baseline 
(cells/µl) 
N/A 136.09     (±113.24) 





25             (1.7%) 
62             (20.6%) 
214          (71.1%) 
Average EFV plasma 
concentration (µg/ml) 
N/A 4.64         (0.6 – 22) 
Mean Haemoglobin level (IU/l) N/A 11.58       (±2.14) 
Median AST level (IU/l) N/A 32           (15 – 228) 
Median ALT level (IU/l) N/A 23.5        (6 – 176) 
N/A = Not applicable 
3.2. PCR/RFLP genotyping 
Genotyping of the CYP1A2 C-163A, CYP2A6 G1093A, CYP2B6 G516T, A785G and C1459T, 
CYP3A4 A-392G, CYP3A5 A6986G, G14690A and 27131-2insT genetic polymorphisms were 
performed using PCR-RFLP. A typical example of PCR/RFLP genotyping is shown in Figure 3.1 
using the genotyping of CYP2B6 G516T polymorphism as an example. Presence of the CYP2B6 
516T variant abolishes a BsrI restriction site, thus, digestion of the 526 bp PCR fragment results in  
two bands (509 and 17 bp) compared to the three bands (268, 241 and 17 bp) obtained when the 
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        MWM      1          2           3          4        5          6          7         8 
Figure 3.1: Genotyping of CYP2B6 G516T is shown on a 2.5% agarose gel. The 100bp plus
molecular weight marker (MWM) was used and the genotypes are represented as follows; G/G = 
lanes 1, 4 and 7, G/T = lanes 2, 3, 5 and 6, with the T/T genotype in lane 8.
3.3. SNaPshot genotyping 
Genotyping of the CYP2B6 A136G and T983C, CYP3A5 C3699T, G19386A and C31611T, ABCB1
A61G, C1236T, C3435T/A, T2677G/A and A4036G genetic polymorphisms were performed using 
SNaPshot. Below in Figure 3.2 we show an example of the chromatograms obtained using ABCB1 
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ABCB1 A4036G:    A/A genotype              A/G genotype             G/G genotype 
 
ABCB1 T2677G/A: 
       G/G genotype         T/T genotype         G/T genotype           G/A genotype          T/A genotype 
 
 Figure 3.2: SNaPshot genotyping of the ABCB1 A4036G and T2677G/A genetic polymorphisms 
using capillary electrophoresis. A reverse internal SNaPshot primer was used in ABCB1 T2677G/A 
genotyping and the 2677T allele, 2677G allele and 2677A allele is therefore represented as a 2677A 
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3.4. Allele and genotype frequencies of SNPs 
Tables 7 and 8 show the genotype and allele frequencies of the genetic polymorphisms in CYP1A2,
CYP2A6, CYP2B6, CYP3A4/5 and ABCB1 in the healthy participants as well as the HIV/AIDS
patients. The allele and genotype frequencies were first established in the healthy participants and
then used to target genotyping in the HIV/AIDS patients. Allele and genotype frequencies were
expected to be similar between healthy participants and HIV/AIDS patients, however, genotype
frequencies differed significantly between these two groups for the CYP2B6 T983C, CYP3A4 A-
392G, CYP3A5 A6986G, CYP3A5 27131-2insT, ABCB1 A61G, ABCB1 C3435T/A and ABCB1
T2677G/A SNPs. Allele and genotype frequencies differ between ethnic groups and the differences
observed between the healthy participants and HIV/AIDS patients can be as a result of small
differences in the composition of the healthy controls compared to patients with respect to different
ethnic groups or possibly undetected genotyping errors. Hardy-Weinberg equilibrium (HWE) was
calculated in the healthy research participants and HIV/AIDS patients and genotyping results were
confirmed by cycle sequencing. The genotype frequencies of four SNPs deviated from HWE in the
healthy participants and patients and could be an indication of genotyping errors in the CYP2B6
A136G, CYP3A4 A-392G, CYP3A5 A6986G and CYP3A5 27131-2insT SNPs. The variant allele
frequencies of all the SNPs were above 0.01, except for the CYP3A5 C3699T, CYP3A5 G19386A
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Table 7: Genotype frequencies of genetic polymorphisms in CYP1A2, CYP2A6, CYP2B6, 








P-value HWE (p-value) 





CYP1A2:  -163C>A 
          
      104 
          




C/C 8 (0.077) 18 (0.130)  
0.755  
 
C/A 44 (0.423) 70 (0.507) 0.0765 0.397 
A/A 52 (0.500) 50 (0.362)   
CYP2A6: 1093G>A       160          293    
G/G 135 (0.444) 253 (0.863)  
0.284  
 
G/A 25 (0.156) 35 (0.119) 0.1470 0.007 
A/A 0 (0.000) 5 (0.017)   
CYP2B6: 136A>G       160          295    
A/A 141 (0.881) 248 (0.841)  
0.006  
 
A/G 16 (0.100) 33 (0.112) 0.2693 0.000 
G/G 3 (0.019) 14 (0.047)   
CYP2B6: 516G>T       160          295    
G/G 64 (0.400) 107 (0.363)  
0.726  
 
G/T 76 (0.475) 133 (0.451) 0.2356 0.233 
T/T 20 (0.125) 55 (0.186)   
CYP2B6: 785A>G         160           293    
A/A 63 (0.394) 110 (0.375)  
0.488  
 
A/G 78 (0.488) 132 (0.451) 0.2945 0.297 
G/G 19 (0.119) 51 (0.174)   
CYP2B6: 983T>C       156          290    
T/T 148 (0.949) 253 (0.872)  
0.742  
 
T/C 8 (0.051) 32 (0.110) 0.0261 0.002 
C/C 0 (0.000) 5 (0.017)   
CYP2B6: 1459C>T       163          293    
C/C 158 (0.969) 289 (0.986) 0.2921 0.842  0.906 
C/T 5 (0.031) 4 (0.014)   
CYP3A4: -392A>G       101           86    
A/A 22 (0.218) 9 (0.105)  
0.0002  
 
A/G 30 (0.297) 38 (0.442) 0.0414 0.954 
G/G 49 (0.485) 39 (0.453)   
CYP3A5: 3699C>T       160          295    
C/C 160 (1.000) 295 (1.000)    
CYP3A5: 6986A>G       155          295    
A/A 100 (0.645) 211 (0.715)  
0.003  
 
A/G 41 (0.265) 77 (0.261) 0.0056 0.994 
G/G 14 (0.090) 7 (0.024)   
CYP3A5: 14690G>A       162          290    
G/G 113 (0.698) 194 (0.669)  
0.777  
 
G/A 44 (0.272) 91 (0.314) 0.4457 0.121 
A/A 5 (0.031) 5 (0.017)   
CYP3A5:27131-2insT        161          294    
-/- 146 (0.907) 282 (0.959)  
0.0001  
 
-/T 10 (0.062) 5 (0.017) 0.0313 0.000 
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CYP3A5: 19386G>A       160          295 
G/G 160 (1.000) 295 (1.000) 
CYP3A5: 31611C>T       157          295 
C/C 70 (0.446) 144 (0.488) 
0.391 C/T 66 (0.420) 114 (0.386) 0.6912 0.059 
T/T 21 (0.134) 37 (0.125) 
ABCB1: 61A>G       160          295 
A/A 157 (0.981) 295 (1.000) 
0.905 A/G 3 (0.019) 0 (0.000) 0.0430 
ABCB1: 3435C>T/A       160          295 
C/C 102 (0.638) 233 (0.790) 
0.530 C/T 50 (0.313) 59 (0.200) 0.0004 0.730 
T/T 8 (0.050) 3 (0.010) 
ABCB1: 4036A>G       160          289 
A/A 98 (0.613) 189 (0.641) 
0.253 A/G 56 (0.350) 96 (0.325) 0.8368 0.605 
G/G 6 (0.038) 10 (0.034) 
ABCB1: 1236C>T       160          295 
C/C 112 (0.700) 235 (0.797) 
0.564 C/T 45 (0.281) 56 (0.190) 0.0687 0.750 
T/T 3 (0.019) 4 (0.014) 
ABCB1: 2677T>G/A       157          294 
G/G 132 (0.841) 283 (0.963) 
0.563 
G/T 21 (0.134) 9 (0.031) 
T/T 2 (0.013) 0 (0.000) <0.0001 0.789 
T/A 1 (0.006) 1 (0.003)
G/A 1 (0.006) 1 (0.003)
N=number of individuals 
Table 8: Allele frequencies of genetic polymorphisms in CYP1A2, CYP2A6, CYP2B6, CYP3A4/5 
and ABCB1.






CYP1A2:  -163C>A         208         276 
C 60 (0.289) 106 (0.384) 0.0333 
A 148 (0.712) 170 (0.616) 
CYP2A6: 1093G>A         320        586 
G 295 (0.922) 541 (0.923) 1.0000 
A 25 (0.078) 45 (0.077) 
CYP2B6: 136A>G         320         590 
A 298 (0.931) 529 (0.897) 0.0917 
G 22 (0.069) 61 (0.103) 
CYP2B6: 516G>T         320         590 
G 204 (0.638) 347 (0.588) 0.1557 
T 116 (0.363) 243 (0.412) 
CYP2B6: 785A>G         320         586 
A 204 (0.638) 352 (0.601) 0.2851 
G 116 (0.363) 234 (0.399) 
CYP2B6: 983T>C         312         580 
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C 8 (0.026) 42 (0.072)  
CYP2B6: 1459C>T        326        586  
C 321 (0.986) 582 (0.993) 0.2944 
T 5 (0.015) 4 (0.007)  
CYP3A4: -392A>G         202         172  
A 74 (0.366) 56 (0.326) 0.4463 
G 128 (0.634) 116 (0.674)  
CYP3A5: 3699C>T         320         590  
C 320 (1.000) 590 (1.000)  
CYP3A5: 6986A>G         310         590  
A 241 (0.777) 499 (0.846) 0.0131 
G 69 (0.223) 91 (0.154)  
CYP3A5: 14690G>A         324         580  
G 270 (0.833) 479 (0.826) 0.8540 
A 54 (0.167) 101 (0.174)  
CYP3A5:27131-2insT         322         588  
- 302 (0.938) 569 (0.968) 0.0399 
T 20 (0.062) 19 (0.032)  
CYP3A5: 19386G>A         320         590  
G 320 (1.000) 590 (1.000)  
CYP3A5: 31611C>T         314         590  
C 206 (0.656) 402 (0.681) 0.4571 
T 108 (0.344) 188 (0.317)  
ABCB1: 61A>G         320         590  
A 317 (0.991) 590 (1.000) 0.0432 
G 3 (0.009) 0 (0.000)  
ABCB1: 3435C>T/A         320        590  
C 254 (0.794) 525 (0.890) 0.0001 
T 66 (0.206) 65 (0.110)  
ABCB1: 4036A>G         320         590  
A 252 (0.788) 474 (0.803) 0.6042 
G 68 (0.213) 116 (0.197)  
ABCB1: 1236C>T         320         590  
C 269 (0.841) 526 (0.892) 0.0362 
T 51 (0.159) 64 (0.108)  
ABCB1: 2677T>G/A        314         586  
G 286 (0.911) 576 (0.980) <0.0001 
T 26 (0.083) 10 (0.017)  
A 2 (0.006) 2 (0.030)  
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3.5. Linkage disequilibrium and Haplotype analysis 
Linkage disequilibrium (LD) analysis was performed for the five SNPs in the CYP2B6 gene, the six
SNPs in CYP3A5 and the five SNPs in ABCB1. High pairwise linkage disequilibrium coefficients
(D´and r
2
) indicated that CYP2B6 G516T and A785G are in tight linkage disequilibrium and are
reported in Table 9, while the LD plots are shown in Figure 3.3. No tight LD was observed between
the genetic polymorphisms in CYP3A5 or ABCB1 (Table 9). D´ and r
2
are both measures of linkage
disequilibrium and should therefore be similar; however, these coefficients are not independent of
allelic frequencies and the r
2
coefficient is a correlation coefficient which is preferred by the
HapMap project and therefore used in this study.
Table 9: Linkage disequilibrium analysis of CYP2B6, CYP3A5 and ABCB1.
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Figure 3.3 Linkage disequilibrium (LD) analysis of genetic polymorphisms in CYP2B6, 
CYP3A5 and ABCB1. 1and 2) D´ and r
2
 linkage disequilibrium coefficients of SNPs in CYP2B6. 3 
and 4) D´ and r
2
 linkage disequilibrium coefficients of SNPs in CYP3A5. 5 and 6) D´ and r
2
 linkage 
disequilibrium coefficients of SNPs in ABCB1. 
Haplotype analysis demonstrated the presence of four, five and seven frequent inferred haplotypes 
for CYP2B6, CYP3A5 and ABCB1, respectively. The inferred haplotypes with a frequency below 5% 
as well as the inferred haplotypes with a significant difference in frequency between the healthy 
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Table 10: Haplotype analysis of CYP2B6, CYP3A5 and ABCB1 in the healthy research 



















   
1 A G A C T  0.5441 0.4717 
2 A G A C C  0.0170 0.0624 
3 A T G C T  0.3381 0.3506 
4 G T G C T  0.0095 0.4690 
CYP3A5 C3699
T 
A6986G G14690A T-ins G19386A C31611T   
5 C A G - G C 0.4111 0.4857 
6 C A G - G T 0.1456 0.1649 
7 C A A - G C 0.1700 0.1649 
8 C G G - G T 0.1867 0.1436 





   
10 A C A C G  0.6018 0.6754 
11 A C G C G  0.1457 0.1708 
12 A T A T G  0.0305 0.0573 
13 A T A C G  0.0684 0.0343 
14 A T A T T  0.0455 0.0013 
15 A T G T G  0.0396 0.0077 
16 A C G T A  0.0074 0.0086 
 
3.6. Correlation with EFV plasma concentration 
The distribution of EFV plasma concentrations in the HIV/AIDS patients was investigated and a 
large degree of inter-individual variability (38-fold) was observed, which has implications on ARV 
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Figure 3.4: The average EFV plasma concentration levels.
The CYP2B6 516T/T (P<0.0001), 785G/G (P<0.0001) and 983C/C (P=0.027) genotypes were 
independently associated with high average EFV plasma concentrations. The current assumption that
the CYP1A2 -163A allele affects enzyme activity only in smokers but not in non-smokers is
supported by our results as no significant difference in EFV concentrations are observed in non-
smokers (P=0.3523), but a very small number (n=7) of smokers were present in this study and
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Figure 3.5: The CYP2B6 G516T, A785G and T983C genetic polymorphisms were significantly 
associated with high EFV plasma concentrations. CYP1A2 C-163A showed a trend towards low 
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The combined effect of the associated genetic polymorphisms in CYP2B6 and CYP1A2 were 
investigated and is shown in Figure 3.6. The CYP2B6 516T, 785G, 983C and CYP1A2 -163C alleles 
are defined as high risk alleles. The individuals with four, five and six high risk alleles have 
significantly higher EFV plasma concentrations compared to individuals without the CYP2B6 516T, 
785G, 983C and CYP1A2 -163C alleles. 
Figure 3.6: The combined effect of CYP2B6 516T, 785G, 983C and CYP1A2 -163C alleles on the 
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3.7. Correlation of EFV with disease severity 
Comparison of EFV plasma levels in the different disease stages showed no significant difference 
(P=0.2842), but a trend towards high mean EFV levels in the more advanced stages of disease and 
disease severity was observed and could be explained by virologic failure as a result of the 
development of ADRs due to high EFV levels leading to poor adherence to treatment (Figure 3.7). 
 
 Figure 3.7: Correlation of EFV plasma concentrations with disease severity. 
 
3.8. Correlation of genotypes with change in ART regimen  
 
Information regarding a change in ARV regimen was available and investigated for the CYP2B6 
G516T, A785G, T983C and CYP1A2 C-163A SNPs. A higher percentage of individuals with the 
CYP2B6 516T/T (96%) and 785G/G (98%) genotypes changed treatment within one year after 
initiation compared to the CYP2B6 516G/G (82%) and 785A/A (76%) genotypes. The difference can 
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effects. The CYP2B6 983C/C (40%) and CYP1A2 -163A/A (63%) genotypes was shown to result in 
fewer individuals with a change in treatment compared to the CYP2B6 983T/T (89%) and CYP1A2 -
163C/C (71%) genotypes. HIV/AIDS patients with the CYP1A2 -163A/A genotype and low EFV 
plasma concentrations were less likely to develop ADRs and to change treatment, however very few 
individuals have the CYP2B6 983C/C genotype (Table 11). 
 




Three months Six months One year 
CYP2B6 516G/G 102 6% 26% 82% 
CYP2B6 516G/T 125 12% 39% 90% 
CYP2B6 516T/T 53 9% 34% 96% 
CYP2B6 785A/A 105 5% 23% 76% 
CYP2B6 785A/G 125 13% 42% 93% 
CYP2B6 785G/G 49 10% 37% 98% 
CYP2B6 983T/T 240 9% 35% 89% 
CYP2B6 983T/C 30 10% 33% 93% 
CYP2B6 983C/C 5 0% 0% 40% 
CYP1A2 -163C/C 17 18% 59% 71% 
CYP1A2 -163C/A 64 8% 28% 61% 
CYP1A2 -163A/A 49 8% 27% 63% 
 
 
3.9. Anomalies in EFV plasma concentration 
About 5% (n=7) of the total samples (n=138) had drug levels below the EFV therapeutic range of 
1.00 µg/ml, while approximately 31% (n=48) of samples had concentrations above the therapeutic 













66 | P a g e
Figure 3.8: The average EFV concentration levels presented according to EFV therapeutic 
range (1-4 µg/ml).
Two of the four individuals (patients one and four) with the CYP2B6 516G/G genotype, but high 
EFV levels, have the CYP2B6 983C allele resulting in decreased enzyme activity. Patient two has
decreased CYP3A5 and ABCB1 enzyme activity as a result of the CYP3A5 6986G allele and ABCB1
1236T and 3435T alleles and patient 3 has the CYP3A5 27131-2insT polymorphism associated with
reduced CYP3A5 enzyme activity. All three individuals with low EFV plasma concentrations, but
the CYP2B6 516G/T or 516T/T genotypes, have the CYP1A2 -163A allele associated with increased
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Table 12: Genotypes for patients with EFV plasma concentrations above or below the 
therapeutic range. 


















CYP1A2  C-163A A/A C/A C/A C/A C/A A/A C/A 
CYP2A6  G1093A G/A G/G G/G G/G G/G G/G G/G 
CYP2B6  A136G A/A A/G A/A A/A A/A G/G A/A 
CYP2B6  G516T G/G G/G G/G G/G G/T G/T T/T 
CYP2B6  A785G A/A A/A A/A A/A A/G A/G G/G 
CYP2B6  T983C T/C T/T T/T C/C T/T T/T T/T 
CYP2B6  C1459T C/C C/C C/C C/C C/C C/C C/C 
CYP3A4  A-392G N/A N/A N/A N/A N/A G/G N/A 
CYP3A5  C3699T C/C C/C C/C C/C C/C C/C C/C 
CYP3A5  A6986G A/A A/G A/A A/A A/A A/A A/A 
CYP3A5  G14690A G/A G/G G/G G/G G/G G/A G/G 
CYP3A5  27131-
2insT 
-/- -/- -/T -/- -/- -/- -/- 
CYP3A5  G19386A G/G G/G G/G G/G G/G G/G G/G 
CYP3A5  C31611T C/T C/T C/C C/T C/C C/C C/C 
ABCB1  A61G A/A A/A A/A A/A A/A A/A A/A 
ABCB1  C1236T C/C C/T C/C C/T C/T C/C C/C 
ABCB1  C3435T/
A 
C/C C/T C/C C/C C/C C/C C/C 
ABCB1  T2677G/
A 
G/G G/G G/G G/G G/G G/G G/G 
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Chapter 4: Discussion 
4.1. Study subjects and clinical parameters 
Genetic polymorphisms with an allele frequency of 0.1 could be detected with 95% confidence given 
the sample size of 138 samples. The study cohort size (n=464) consisting of 163 healthy research
participants and 301 HIV/AIDS individuals was therefore more than adequate. The majority of
HIV/AIDS patients were females and this might be the reason for the very low smoking and alcohol
use among the study subjects because generally among South African Black people, smoking and 
alcohol consumption is less common in women than in other racial groups[148]. The current study
cohort had few smokers thus, it was impossible to evaluate the effect of tobacco smoking on EFV
plasma concentration, although, other studies alluded to the possibility of CYP2A6 induction among 
smokers and consequently reduced EFV plasma concentration. 
Clinical parameters such as CD-4 cell count, viral load, disease stage, haemoglobin, AST and ALT
levels were used as an indication of ARV treatment efficacy, underlying liver disease and disease
progression in the HIV/AIDS patients. As expected, EFV-containing HAART led to a general (48%)
increase in CD-4 cell count (cells/µl) and a 94% decrease in viral load (copies/ml) baseline levels
when compared to levels at 6 months. However, a single individual had a 68% increase in viral load
between baseline and 6 months after treatment initiation and this individual had to be switched ARV
regimens four times since treatment initiation. First from AZT_3TC_NVP to
AZT_3TC_LPV/r_TDF; AZT_LPV/r_TDF and back to AZT_3TC_LPV/r_TDF. Interestingly, this
individual had the CYP2B6 516G/T, 785A/G and 983T/C genotypes, associated with high EFV
plasma concentrations and development with ADRs. Genotyping this patient for the CYP2B6 G516T,
A785G and T983C SNPs before treatment initiation could have been used to reduce the drug dose
and avoided the change to more expensive ARV regimens. The AST and ALT levels (119 IU/l and
71 IU/l, respectively) of this patient were above the average AST and ALT levels of 43 IU/l and 30
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participants were above the normal AST range of 10-35 IU/l, but the average ALT levels (30 IU/l) 
were however not above the normal range of 9-40 IU/l. Elevated AST and ALT levels are as a result 
of underlying liver disease and complicate treatment. Elevated ALT levels were therefore 
significantly linked to high average plasma drug concentrations.  
Failure of reduction in viral load and emergence of opportunistic infections after six months was 
associated with ARV switching. Sustained viral load after 6 months and the presence of 
opportunistic infections are indications of possible treatment failure or non-adherence. On the other 
hand, other studies have shown that high EFV plasma concentrations are associated with 
development of adverse drug events leading to drug discontinuation[17, 149, 150]. Although non-
adherence plays a role in poor drug response, it has to be taken into account that poor metabolism 
can also result in low drug levels which lead to virologic failure.  
4.2. Allele and genotype frequencies of SNPs 
To our knowledge, the present study is the first report on the allele and genotype frequencies of the 
following genetic polymorphisms in the South African population; CYP2A6 G1093A, CYP2B6 
A136G and T983C, CYP3A5 G19386A and C31611T as well as ABCB1 A4036G. This data 
contribute to the accumulation of information on genetic variants of pharmacogenetics relevance 
among Africans. 
The allele frequencies of the genetic polymorphisms in the healthy research participants (presented 
in Tables 7 and 8) were also compared to the allele frequencies in other African, African-American 
and Caucasian populations (Tables 13 and 14). It is clear that there are significant differences in the 
allele frequencies between the African populations and the Caucasians for example the allele 
frequency of the ABCB1 3435T allele in African populations ranges from 0.07 to 0.11, but is present 
at a frequency of almost 0.6 in Caucasian individuals. These differences show that universal 
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compared with other African populations also exist. Of particular interest, the allele frequency of the
CYP1A2 -163A allele was similar in the Yoruba (0.57) and African-American (0.54) individuals.
However, the -163A allele occurred at a frequency of 0.71 in the present study and at 0.72 among
Caucasians (P=0.9092). The CYP1A2 -163A allele frequencies are in concordance with what has 
been reported previously in Africans (0.55), Asians (0.65) and Caucasian (0.7) individuals. The
African population can therefore not be treated as a single population and drug dose needs to be
adjusted according to ethnic group and ultimately based on the genotypes of an individual. The allele
frequencies of the CYP2A6 1093A allele were significantly different to the frequency in the Yoruba
(P=0.0082) and Caucasian (P<0.0001) individuals. The CYP2B6 136G allele was more frequent in
the South Africans than in the Caucasians (P=0.0025). Interestingly, the frequency of the CYP2B6
516T allele only differed significantly from the frequency reported in the Xhosa individuals
(P=0.0046), while the 785G allele was more frequent in the South Africans than in the Caucasians
(P=0.0013). The frequency of the CYP2B6 983C allele in the South Africans differed from both the
Xhosa and Yoruba individuals (P<0.0001 and P=0.0003). The allele frequencies of CYP2B6 1459T
allele, CYP3A5 6986G allele, CYP3A5 31611T allele and ABCB1 1236T allele differed from the 
Caucasians (P=0.0007, P<0.0001, P<0.0001 and P<0.0001, respectively), while the allele
frequencies of the CYP3A5 27131-2insT and ABCB1 4036G allele were different to the frequencies
reported in the Yoruba individuals (P<0.0001). The frequency of CYP3A4 -392G allele was similar
to the African-Americans, but different from the other populations (P=0.0166, P=0.0006 and
P<0.0001). The same was observed for the CYP3A5 14690A allele compared to the Xhosa, Yoruba,
Caucasian, Luhya and Maasai individuals (P=0.0001, P=0.0002, P=0.0009, P<0.0001 and P=0.0088,
respectively). The frequency of the ABCB1 3435T allele were different among all the populations,
while the frequency of the ABCB1 2677T/A alleles differed significantly from the Yoruba individuals
(P<0.0001) and Caucasians (P<0.0001). The differences in allele frequencies between the African
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universal dosages. Similarly, fine scale genetic structure exists within the African population and can 
therefore not be treated as a single population. 
Table 13: Allele frequencies in the healthy research participants, Xhosa individuals, Yoruba 


























CYP1A2 -163A 0.712 N/A 0.566 N/A N/A 0.543 0.721 
CYP2A6 1093A 0.078 N/A 0.131 N/A N/A 0.167 0.004 
CYP2B6 136G 0.069 N/A N/A N/A N/A N/A 0.008 
CYP2B6 516T 0.363 0.200 0.420 0.310 0.370 0.467 0.270 
CYP2B6 785G 0.363 N/A 0.455 N/A N/A 0.462 0.214 
CYP2B6 983C 0.026 0.170 0.124 0.070 0.020 0.038 0.000 
CYP2B6 1459T 0.015 N/A 0.042 N/A N/A 0.000 0.091 
CYP3A4 -392G 0.634 0.770 0.792 N/A N/A 0.679 0.023 
CYP3A5 3699T 0.000 N/A N/A N/A N/A N/A N/A 
CYP3A5 6986G 0.223 N/A 0.155 N/A N/A 0.367 0.964 
CYP3A5 14690A 0.167 0.200 0.168 0.250 0.140 0.115 0.000 
CYP3A5 27131-
2insT 
0.062 N/A 0.000 N/A N/A 0.214 0.000 
CYP3A5 19386A 0.000 N/A N/A N/A N/A N/A N/A 
CYP3A5 31611T 0.344 N/A 0.274 N/A N/A 0.370 0.960 
ABCB1 61G 0.009 0.000 0.000 N/A N/A 0.000 0.100 
ABCB1 1236T 0.159 0.130 0.124 0.110 0.140 0.136 0.451 
ABCB1 3435T 0.206 0.110 0.111 N/A 0.840 0.071 0.571 
ABCB1 2677T/A 0.083/0.00
6 
N/A 0.00 N/A N/A 0.077/0.00 0.34/0.042 
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Table 14: Comparison (p-values) of the allele frequencies in the healthy research participants 
with the Xhosa individuals, Yoruba individuals, Luhya individuals, Maasai individuals, 
African-American and Caucasian populations. 











































1093A N/A 0.0082 N/A N/A 0.0911 <0.0001 
CYP2B6 rs35303
484 
136G N/A N/A N/A N/A N/A 0.0025 
CYP2B6 rs37452
74 
516T 0.0046 0.2502 0.4900 0.9057 0.3028 0.0589 
CYP2B6 rs22793
43 
785G N/A 0.0949 N/A N/A 0.3028 0.0013 
CYP2B6 rs28399
499 
983C <0.0001 0.0003 0.1729 1.000 0.6149 0.0302 
CYP2B6 rs32113
71 
1459T N/A 0.1295 N/A N/A 1.000 0.0007 
CYP3A4 rs27405
74 
-392G 0.0166 0.0006 N/A N/A 0.7281 <0.0001 
CYP3A5 rs55817
950 
3699T N/A N/A N/A N/A N/A N/A 
CYP3A5 rs77674
6 
6986G N/A 0.1107 N/A N/A 0.0542 <0.0001 
CYP3A5 rs10264
272 





N/A 1.000 N/A N/A <0.0001 1.000 
CYP3A5 rs28383
479 
19386A N/A N/A N/A N/A N/A N/A 
CYP3A5 rs15524 31611T N/A 0.1480 N/A N/A 0.7302 <0.0001 
ABCB1 rs92825
64 
61G 1.000 1.000 N/A N/A 1.000 0.7786 
ABCB1 rs11285
03 
1236T 0.6006 0.3728 0.1760 0.7488 0.8171 <0.0001 
ABCB1 rs10456
42 
3435T 0.0468 0.0097 N/A <0.0001 0.0276 <0.0001 
ABCB1 rs20325
82 
2677T/A N/A <0.0001 N/A N/A 0.8678 <0.0001 
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4.3. Linkage disequilibrium and Haplotype analysis 
Tight LD (D´=0.967 and r
2
=0.918) was observed only between the CYP2B6 G516T and A785G
genetic polymorphisms in the South African population which is similar to studies done among
Caucasians and Asians[84]. This observation has important implications for genetic screening
preceding ARV therapy and therefore only screening for the G516T polymorphism is necessary in
South African HIV/AIDS patients. With respect to the linkage between G516T and T983C, other
studies in Caucasians, reported almost 100% linkage of the three SNPs. The A785G SNP is often
inherited together with both the G516T and T983C SNPs and these three polymorphisms were
consequently found to be in tight LD[88]. However, in South Africans (our current study), West
Africans and African-Americans the LD block between G516T and A785G does not include the
T983C polymorphism[151]. Genetic polymorphisms in the CYP3A5 or ABCB1 genes were not in LD
in the South African population, which is in contrast to the tight LD observed between ABCB1
C1236T, C3435T/A and T2677G/A among individuals of Caucasian origin[152]. The observation of
a greater degree of LD among the Caucasians than in the African populations is explained by a 
possible bottleneck that occurred with migration from Africa[153]. However, the differences in
inferred haplotypes, further confirms the need for consolidated studies among the African Black
population to discover relevant haplotype blocks as well as good tag SNPs. This may be
accomplished by whole genome sequencing of more samples from Africans.
The CYP2B6 inferred haplotypes frequently observed in the South African individuals corresponded 
to the AGACT (CYP2B6*1), AGACC (CYP2B6*18), ATGCT (CYP2B6*7) and GTGCT 
(CYP2B6*11) haplotypes reported previously (www.cypalleles.ki.se). The following inferred 
haplotypes were identified in CYP3A5; CAG-GC (CYP3A5*1A), CAG-GT (CYP3A5*1D), CAA-GC 
(CYP3A5*6), CGG-GT (CYP3A5*3A) and CGG-GC (CYP3A5*3C). Previous studies have reported 
the identification of the ABCB1 893Ala-containing CGC haplotype (ABCB1 1236C, 2677G and 
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ABCB1 893Ser-containing haplotype (ABCB1 1236T, 2677T and 3435T alleles) was defined by Kim 
et al. [154] and present at a low frequency in this study. Inferred haplotypes that are different 
combinations of the three common ABCB1 SNPs for example 1236T, 2677G and 3435T were 
observed at low frequencies as a result of the lack of LD between these three SNPs in the South 
Africans.  
4.4. Correlation of genotypes with efavirenz plasma concentrations 
Efavirenz plasma concentration levels were obtained at two time-points on average two hours apart 
and the change in plasma concentrations were calculated. The change in EFV concentration can be 
influenced by a number of factors like the time of dosing, food-intake, underlying liver disease and 
co-administration of non-ARV medication. The study subjects were grouped according to the 
therapeutic range of EFV (1 µg/ml - 4 µg/ml).  Individuals with sub-therapeutic plasma EFV 
concentration levels (<1.00 µg/ml) could have been due to any of the following; poor compliance, 
increased metabolism at another loci that metabolises EFV and concomitant treatment with other 
drugs. Co-administration of other drugs could induce the enzymes involved in EFV metabolism and 
this can most likely lead to virologic failure. EFV concentration levels above 4.00 µg/ml were most 
likely due to poor metaboliser status at the loci that metabolises EFV or concomitant EFV treatment 
with other drugs either indicated for other diseases or for recreation, which had inhibitory effects on 
the system that metabolises EFV. The inhibitory effects on EFV metabolism would lead to increased 
EFV plasma levels, decreased viral load but inadvertently, increased adverse EFV effects such as 
CNS toxicity as observed by Marzolini et al. [17]. The 5% and 31% of individuals with EFV plasma 
concentrations below and above the therapeutic range is higher than previously reported in 
Caucasian individuals[155]. The CYP2B6 G516T SNP is well characterised as a risk factor of poor 
EFV metabolism[84]. The average EFV plasma concentrations of the HIV/AIDS patients were 
therefore grouped according to CYP2B6 G516T genotypes to identify other clinical or genetic factors 
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with the CYP2B6 516G/G genotype, possibly pointing to the existence of other mutations in CYP2B6
that have not yet been reported and these should be sequenced. On the other hand, the three
individuals had low EFV concentrations levels yet they were carrying the CYP2B6 516T/T genotype,
which points more to the involvement of other genes in the metabolism of EFV if non-compliance
can be ruled out. Indeed, the four individuals with high EFV plasma concentrations but carrying the
fast CYP2B6 516G/G genotype all had other mutations in CYP2B6 and other genes including
CYP2A6 and CYP3A5. The first individual have the CYP1A2 -163A/A genotype, the CYP2A6
1093G/A genotype, the CYP2B6 983T/C genotype, the CYP3A5 14690G/A and 31611C/T genotypes.
The second individual have the following genotypes; CYP1A2 -163C/A, CYP3A5 6986A/G and
31611C/T, CYP2B6 136A/G, ABCB1 3435C/T and 1236C/T. Individual three is heterozygous for the
CYP1A2 -C163A and the CYP3A5 27131-2insT SNPs, while the fourth individual have the following
genotypes; CYP2B6 983C/C, CYP3A5 31611C/T and ABCB1 1236C/T. The combined effects of
these additional mutations were probably the reason for slow metabolism of EFV. It is interesting to
report that the three individuals with low EFV concentrations yet carrying slow CYP2B6 516T/T
genotype, carried the CYP1A2 -163A variant which has been associated with increased inducibility
and activity of CYP1A2[59, 156, 157]. 
In general, the CYP2B6 G516T and A785G variants showed significant correlation with EFV
concentrations. CYP1A2 C-163A SNP showed a trend towards significant correlation with EFV
plasma levels. Notably, of the four patients with high EFV concentrations one of them presented
with AST and ALT levels above the average of the study cohort (43 IU/l and 30 IU/l) possibly
pointing to underlying liver disease.
The influence of genetic polymorphisms on EFV plasma concentrations was further investigated to 
identify polymorphisms with clinical relevance. The presence of the CYP2B6 516T, 785G and 983C 
variants were associated with significantly higher EFV plasma concentrations, while the CYP1A2 -
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CYP2B6 516T, 785G and 983C variants are in agreement with  other studies involving Caucasians, 
Africans and Asians[82, 84-89, 158]. Our result further confirm previous findings on CYP2B6 516T 
in the South African population[47, 159] which showed an association of this variant with high EFV 
plasma levels. However, the effects of the other CYP2B6 SNPs on EFV levels as well as the inferred 
haplotypes, has not been reported before in this population. Combining the CYP2B6 G516T and 
A785G SNPs did not improve prediction of EFV plasma concentration, because the expected lower 
EFV plasma concentration in the presence of the A785G polymorphism is masked by the presence of 
the G516T polymorphism (D´ = 0.967 and r
2
 = 0.913)  and this is in agreement to earlier 
reports[160]. The CYP2B6 983C variant was associated with high EFV concentration levels in this 
study, confirming earlier reports in Caucasians and  Asians[20, 88]. Five individuals with the 
CYP2B6 983C/C genotype were identified in this study, of which two whose EFV plasma levels 
were available, had more than 5-fold higher EFV plasma concentrations with respect to the 
therapeutic range upper limit. In a recent study by Schipani et al. [89], no CYP2B6 983C/C 
homozygotes were reported. The CYP2B6 983C variant has been associated with substantial 
differences in EFV and NVP exposure among individuals of African and Caucasian ancestry[20, 88, 
161]. The G516T and T983C SNPs together had an additive effect and were associated with an 
almost 2-fold higher EFV concentrations, a finding in agreement to reports by Wyen et al. [161] and 
Schipani et al. [89]. These observations suggest that CYP2B6 polymorphisms can be used as 
biomarkers of EFV plasma levels further arguing for genotyping-assisted dosing with respect to use 
of EFV[85, 89, 162]. Already, suggestions based on pharmacogenetics knowledge are being 
proposed, such as gradual reductions in EFV dose from 600mg/day to 400 mg/day or 200mg/day for 
intermediate metaboliser and poor metaboliser patient groups, respectively[20, 163]. Nevirapine, 
which is another substrate of CYP2B6 has been suggested to be dosed twice-daily (200mg) instead of 
once-daily (400mg) to avoid sub-therapeutic drug exposure in the fast metaboliser with the CYP2B6 
516G/G genotype, while also ensuring that EFV levels would not go above the therapeutic range in 
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CYP2B6 983T/C genotype. The CYP1A2 C-163A polymorphism is located in intron 1, modifying a
transcription factor binding site and has been associated with increased CYP1A2 inducibility[52,
157]. In the current study, the CYP1A2 -163A variant was associated with low EFV plasma 
concentrations although not statistically significant. The influence of the CYP1A2 -163A variant was
prominent in carriers of CYP2B6 516G/T or 516T/T genotypes who displayed low EFV levels, 
contrary to expectations of high levels. Our findings may help to clarify that the CYP1A2 -163A
variant is most likely associated with increased induction or enzyme activity than the contrary[58,
164].
The only SNP genotyped for in CYP2A6, 1093G>A, did not show any correlation with EFV plasma
levels, which is contrary to the observation by Kwara et al. [165] in a Bantu-speaking Ghanaian
population, who reported a nearly 2-fold higher median EFV concentration in CYP2A6 1093A/A
homozygotes when compared to 1093G/G homozygotes. To really conclude on the effects or role of
CYP2A6, more SNPs should be investigated.
We report no association between genetic polymorphisms in CYP3A4/5 and altered EFV metabolism
which supports the results reported previously[116, 166]. This probably suggests a very minor role
of this ubiquitous and promiscuous enzyme family.
In addition to drug metabolising enzymes, drug transporters also play a role in drug disposition thus;
we investigated 5 SNPs in ABCB1. It is surprising that we did not observe a role for any of the
ABCB1 genetic polymorphisms with EFV concentrations, yet, in a different study among Ugandans, 
the ABCB1 4036G variant resulted in higher EFV plasma concentrations[167]. Previous studies
investigating the potential phenotypic associations for the ABCB1 C1236T, T2677G/A and C3435T/A
polymorphisms bear no consensus and the 1236C/C genotype has been linked to increased drug
response in treatment of glioblastoma patients[168], yet the 1236T/T genotype has also been
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conclusions. There are conflicting reports as well for the role or effects of ABCB1 T2677G/A and 
C3435T/A polymorphisms[170].  
The above mentioned studies reported associations based on the presence or absence of a single 
genetic polymorphism in one of the pharmacogenetically relevant genes. Prediction of response to 
EFV can however not be made based on genotypic data at a single locus. The combined effect of the 
CYP1A2 C-163A and CYP2B6 G516T, A785G and T983C polymorphisms produced a more accurate 
prediction of EFV plasma concentration.  
The predictive ability of the CYP2B6 516T/T, 983C/C and CYP1A2 -163A/A genotypes on EFV
plasma concentrations above the therapeutic range were investigated, however because of the strong
LD between CYP2B6 G516T and A785G only screening for the CYP2B6 G516T SNP is
recommended (Tables 15 and 16). The sensitivity and specificity of the CYP2B6 516T/T genotype is
high compared to that of the CYP2B6 516G/G genotype, but low for the CYP1A2 -163A/A genotype
compared to the CYP1A2 -163C/C genotype. The sensitivity of the CYP2B6 983C/C genotype is
high, but the specificity low and this is as a result of only two individuals with the CYP2B6 983C/C
genotype and EFV concentrations above 4 µg/ml. The combined predictive ability of the CYP2B6
516T/T and CYP1A2 -163A/A genotypes have very high sensitivity and specificity, but low positive
and negative predictive alues showing the clinical utility of testing for these genotypes.
Pharmacogenetic screening for CYP2B6 516T/T and CYP1A2 -163A/A genotypes with high
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Table 15: HIV/AIDS patients with EFV concentration above or below 4 µg/ml 
Genotypes HIV/AIDS patients with EFV 
concentrations >4 µg/ml 
HIV/AIDS patients with EFV 







CYP2B6 516T/T 22 3 
CYP2B6 983T/T  














CYP1A2 -163A/A  15 32 
 










CYP2B6 516T/T Decreased 88% 92% 15% 6% 
CYP2B6 983C/C Decreased 100% 68% 95% 0% 
CYP1A2 -163A/A Increased 
inducibility 
32% 42% 32% 86% 
CYP2B6 516T/T and 
CYP1A2 -163A allele 
Normal 100% 93% 15% 0% 
 
4.5. Correlation of genotypes with change in ART regimen  
 
The change in ART regimen was used as an indication of treatment failure among South African 
HIV/AIDS patients. Individuals with the CYP2B6 516T/T and 785G/G genotypes were more likely 
to change ART regimen. This observation can be explained by the initial development of EFV-
related CNS adverse events within the first month after treatment initiation. The development of 
adverse effects often results in discontinuation of treatment in individuals with high EFV plasma 
concentrations. Fewer patients with the CYP2B6 983C/C and CYP1A2 -163A/A genotypes changed 
treatment and the observation related to CYP1A2 -163A/A can be explained by the low EFV plasma 
concentrations. However, caution should be taken when concluding on the involvement of the 
CYP2B6 983C/C genotype in treatment discontinuation as only five individuals with the 983C/C 
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4.6. Limitations and future directions 
In the current study EFV plasma concentrations were only available for 156 of the 301 HIV/AIDS 
patients. The limitation of using SNaPshot mini-sequencing as genotyping method is the detection of
the dR110 labelled ddGTP (blue) is more sensitive than detection of the other ddNTPs. Patients were
genetically characterized for a small number of known polymorphisms in the major pharmacogenes
involved in EFV metabolism and future studies should firstly investigate the Bantu-speaking South
African population for novel genetic variants in these genes, as the African population harbours to
greatest degree of genetic diversity, and secondly establish the functional role of these genetic
variants and their effect on treatment with a variety of drugs commonly used in treatment of
infectious diseases. The effect of genetic variation in genes encoding proteins responsible for the
regulation of the genes investigated in the current study should also be focussed on in future studies
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Chapter 5: Conclusion 
 
The current study showed that CYP1A2 and CYP2B6 are the main predictors of response to EFV 
treatment in the South African population. The CYP2B6 G516T, A785G and T983C polymorphisms 
were significantly correlated with high EFV plasma concentration levels, whereas the CYP1A2 C-
163A polymorphism showed a trend towards low EFV plasma concentrations. The combined effect 
of the CYP2B6 and CYP1A2 polymorphisms, rather than the influence of single polymorphisms are 
more accurate in predicting the development of ADRs and treatment failure. This strongly suggests 
that pharmacogenetic testing could assist with deciding of the HAART regimen for HIV/AIDS 
treatment in a clinical setting as well as the starting ARV dosage. Pharmacogenetic testing could be 
beneficial in personalization of treatment and avoiding the development of ADRs that are often 
severe and result in hospitalization of patients. A change to a more expensive treatment regimen and 
poor adherence to treatment can also be prevented by dose adjustment. Ultimately, pharmacogenetic 
testing will aid in tailoring currently available treatment for HIV/AIDS and can prevent the 
development of drug resistance resulting from inefficient suppression of HIV replication. In South 
Africa, pharmacogenetic testing is currently not indicated in the South African ART guidelines and 
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Appendix A: Informed consent 
INFORMED CONSENT FOR LEGAL GUARDIANS 
(Applicable where participants are incapable of giving consent). 
Participant number: ____________ _ 
I, the undersigned, * _ _________ , has fully explained the information 
leafl et to the patient, 
and/or his/her legal 
guardian, __________________ ___ _______ _ 
The account I have given explained both the possible ri sks and benefits of the study. 
The patient and/ or his/her legal guardian understand these. The patient and/or his/her 
legal guardian indicated that he/she understands that the patient will be free to 
withdraw from the study at any time for any reason and without j eopardizing his/ her 
subsequent treatment. 
I hereby certify that, the patient and/or his/her legal guardian acting on his/her behalf 
has agreed to parti cipate. I am willing/not willing (delete the inappropriate) to be 
contacted for follow-up studies 
PATI ENT 
Name and Surname (Cap ital letters) Date 
STUD Y DOCTOR AND PERSON ADMIN ISTERING THE CONSENT 
Name (Capital letters) Signature Date 
LEGAL GUA RDIAN 
Name (Capi ta l letters) Signature Date 
WITNESS 
Name (Capi tal letters) Signature Date 
*Name of member of the researcher team who will be administering the informed consent. 
Protocol Number M080707' The role ofpharm3cogcnctlcs on the response 10 treatmen t using ontlretroviral drug~ in South 2 
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Appendix C: EFV plasma concentration assay by LC/MS/MS  
 
Mobile phase A was 10% methanol and mobile phase B was 90% methanol: 10% 10mM of 
ammonium acetate in 0.1% acetic acid v/v. The flow gradient was initially 100% of phase A for 
0.20mins, switched to 100% phase B for 0.21mins, held at 100% phase B for 2.79mins. Then 
returned to 100% phase A for 0.10mins and held for a further 3.90mins prior to the injection of 
another sample. The total run time for each sample was 7.00mins. The flow rate of mobile phase was 
kept constant at 500 μl/min. The volume of injection was 5 μl. 
The plasma calibration curves of EFV (Merck Research Laboratories, Rahway N.J., USA) were 
linear over the range of 0.20-20.00 mg/l. Plasma calibration curves were prepared by spiking EFV in 
drug-free plasma at each calibration concentration. Three quality controls were prepared in the same 
manner (0.3 mg/l, 4 mg/l and 11 mg/l) for EFV. The lower limit of quantification (LLOQ) for EFV 
was 0.10 mg/l. A sample with plasma concentrations below the LLOQ was treated as 40% of LLOQ 
concentration in the data analysis. Samples with plasma concentrations higher than the upper limits 
of quantification were diluted with drug-free plasma and re-analysed. 
Accuracy of the EFV plasma concentration assay was above 90%. The intra-day and inter-day 

























Figure A: EFV plasma calibration curve and chromatogram of plasma LLOQ (Adapted from 
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Appendix D: DNA integrity evaluation 
The average (±SD) DNA concentration was 187.36 ng/µl (±394.60) with concentrations ranging 
from -1.3 ng/µl to 2438.0 ng/µl for the healthy research participants and HIV/AIDS individuals.  
Figure B shows the DNA integrity of DNA samples extracted from the plasma of 9 HIV/AIDS 
individuals using agarose gel electrophoresis. 
                           MWM     1         2         3        4         5       6         7         8         9  
 
 
Figure B: Evaluation of DNA integrity using a 1% agarose gel. The 100bp plus molecular weight 
marker (MWM) was used and lanes 1 to 9 show variability in DNA concentration and quality of the 
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Appendix E: PCR/RFLP genotyping results continued from section 3.2 
Genotyping of the CYP1A2 C-163A, CYP2A6 G1093A, CYP2B6 G516T, A785G and C1459T, 
CYP3A4 A-392G, CYP3A5 A6986G, G14690A and 27131-2insT genetic polymorphisms were 
performed using PCR-RFLP (Figure C). The CYP2A6 G1093A polymorphism created a TaiI 
restriction site and the 1093G allele produced two bands (855 and 191 bp), while digestion of the 
1093A allele resulted in three bands (491, 364 and 191 bp). The CYP2B6 A785G polymorphism also 
abolished a restriction site (StyI) and StyI digestion of the PCR product from the 785A allele 
produced four bands (297, 171, 116 and 56 bp) whereas the 785G allele produced three bands (468, 
116 and 56 bp). The CYP2B6 C1459T polymorphism created a BglII restriction site and the 1459C 
allele generated a single band (1401 bp) whereas the 1459T allele resulted in two bands of 1185 and 
216 bp. The CYP3A5 A6986G polymorphism resulted in the abolishment of an SspI restriction site 
and digestion of the PCR product from the 6986A allele produced three bands (148, 125 and 20 bp) 
whereas the 6986G allele produced two bands (168 and 125 bp). The CYP3A5 G14690A 
polymorphism abolished a DdeI restriction site, while the CYP3A5 27131-2insT SNP created a DdeI 
restriction site. The 14690G allele of the G14690A polymorphism produced four bands (230, 137, 
103 and 25 bp), while the 14690A allele produced three bands (230, 137 and 128 bp). DdeI digestion 
of the PCR product from the 27131-2insT generated four bands of 41, 24, 22 and 20 bp. The allele 
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Figure C: PCR-RFLP genotyping of CYP2A6 G1093A shown on a 1.5% agarose gel. The 100bp 
plus molecular weight marker (MWM) was used and lanes 1 to 7 represent the different G1093A 
genotypes from 7 individuals; A/A = lanes 1, 2 4, 5 and 6, G/G = lane 3 and G/A = lane 7, 
respective. The 100bp plus molecular weight marker (MWM) was also used in PCR-RFLP 
genotyping of CYP2B6 A785G and lanes 1 to 3 represent the different A785G genotypes from 3 
individuals; G/G = lane 1, A/A = lane 2 and G/A = lane 3. Genotyping of CYP2B6 C1459T is shown 
on a 1.5% agarose gel. The 100bp plus molecular weight marker (MWM) was used and the C/C 
genotype is shown in lanes 1 to 4 and the C/T genotype in lane 5. A 4.5% agarose gel was used to 
show the CYP3A5 A6986G genotypes from 3 individuals. The Roche DNA molecular weight marker 
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lane 3. Genotyping of CYP3A5 G14690A is shown on a 4.5% agarose gel, with the Roche DNA 
molecular weight marker V and lanes 1 to 11 representing the different G14690A genotypes from 11 
individuals. G/G = lanes 1, 2, 3, 5, 7, 8, 9 and 10, G/A = lanes 4 and 6 and A/A = lane 11. PCR-
RFLP genotyping of CYP3A5 27131-2insT shown on a 5% agarose gel. The Roche DNA molecular 
weight marker V was used and lanes 1 to 5 represent the different genotypes from 5 individuals. The 
-/- genotype is represented in lanes 1 to 4 and the T/T genotype in lane 5.  
Appendix F: SNaPshot genotyping results continued from section 3.3 
Genotyping of the CYP2B6 A136G and T983C, CYP3A5 C3699T, G19386A and C31611T, ABCB1 
A61G, C1236T, C3435T/A, T2677G/A and A4036G genetic polymorphisms were performed using 
SNaPshot and is shown in Figure D below.  
CYP2B6 A136G 
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CYP2B6 T983C 
    T/T genotype        T/C genotype         C/C genotype 
 
CYP3A5 C3699T and CYP3A5 G19386A 
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CYP3A5 C31611T 
        C/C genotype         T/C genotype       T/T genotype 
 
ABCB1 A61G 
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ABCB1 C1236T  
    C/C genotype         T/C genotype       T/T genotype 
 
ABCB1 C3435T/A 
    C/C genotype            C/T genotype          T/T genotype 
 
Figure D: SNaPshot genotyping of the CYP2B6 A136G and T983C, CYP3A5 C3699T, G19386A 
and C31611T, ABCB1 A61G, C1236T and C3435T/A genetic polymorphisms were performed. 
